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ABSTRACT: Free fatty acid receptor 3 (FFA3, previously GPR41) is activated by
short-chain fatty acids, mediates health effects of the gut microbiota, and is a
therapeutic target for metabolic and inflammatory diseases. The shortage of well-
characterized tool compounds has however impeded progress. Herein, we report
structure−activity relationship of an allosteric modulator series and characterization of
physicochemical and pharmacokinetic properties of selected compounds, including
previous and new tools. Two representatives, 57 (TUG-1907) and 63 (TUG-2015),
showed improved solubility and preserved potency. Of these, 57, with EC50 = 145 nM
and a solubility of 33 μM, showed high clearance in vivo but is a preferred tool in vitro.
In contrast, 63, with EC50 = 162 nM and a solubility of 9 μM, showed lower clearance and seems better suited for in vivo studies.
Using 57, we demonstrate for the first time that FFA3 activation leads to calcium mobilization in murine dorsal root ganglia.
■ INTRODUCTION
Short-chain fatty acids (SCFAs) are produced in large amounts
by the lower gut microbiota and are known to affect human
health in various and often beneficial ways.1 Free fatty acid
receptors 2 and 3 (FFA2 and FFA3) are G protein-coupled
receptors activated by SCFAs and mediate many of the
physiological effects of SCFAs.2,3 The receptors were discovered
and reported simultaneously in 2003 and are co-expressed in
enteroendocrine cells, pancreatic β-cells, some immune cells,
and certain cancers.4−7 Both FFA2 and FFA3 have been
reported to be expressed in the adipose tissue, although most
studies now suggest that only FFA2 is present.6−10 Of the two
receptors, FFA2 has received more attention, showing promise
as a target for the treatment of various metabolic and
inflammatory conditions,6 with one compound reaching clinical
trials for ulcerative colitis before being discontinued due to
limited efficacy, despite the fact that the compound did inhibit
neutrophil infiltration.11
Several studies have also suggested interesting therapeutic
potential for FFA3. For example, Offermanns and co-workers
demonstrated that deletion of FFA2 and FFA3 in combination,
but not individually, improved insulin secretion and glucose
tolerance in mice, indicating that dual antagonism of the
receptors may counteract type 2 diabetes.12 Activation of both
receptors is also reported to counteract cancer development.13,14
FFA3 is linked to hypoxia-induced apoptosis and may have
potential as a target for ischemia/reperfusion-related injury.15
Marsland and co-workers found that FFA3 but not FFA2
mediates the protective effect of circulating SCFAs against
allergic lung inflammation and is therefore of interest for
treatment of allergic asthma.16 FFA3 has also been reported in
both autonomic and somatic sensory ganglia.17 In sympathetic
ganglia, propionate is found to promote sympathetic nervous
system activation and to be involved in regulation of the body
energy balance.18
Most of the studies involving FFA3 have relied on SCFAs as
tools and/or knockout mice. These studies should be
interpreted with caution because SCFAs are generally able to
activate both FFA2 and FFA3 but with different profiles on
human and rodent orthologues19 and because it has been found
that knockout of one receptor may affect the expression of the
other.10 More studies are therefore required to elucidate the
therapeutic potential of FFA3 alone and in combination with
FFA2. An important reason for the paucity in studies on FFA3 is
the lack of well-characterized high-quality tool compounds for
this receptor.20 Studies that use SCFAs often employ propionate
(C3) as a dual agonist of FFA2 and FFA3, acetate as a FFA2-
selective agonist, and butyrate as a FFA3-selective agonist;
however, the selectivity for these compounds are modest at
best.19 Recently, the FFA3-selective SCFA-analogue 1-methyl-
cyclopropylcarboxylate (1-MCPC) has also been employed, but
its potency remains very low.21
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Currently, the only tools for FFA3 with potency in the single-
digit micromolar range are from a series of tetrahydroquinolones
originally disclosed by Arena Pharmaceuticals (represented by 1,
Table 1) and that were subsequently shown to be allosteric
modulators of the receptor.22,23 Although they have occasionally
been used as tools,24−28 moderate potency and the lack of
proper characterization have limited the use of these
compounds. The compounds act as allosteric modulators and
are not affected by mutation of arginine residues in the
orthosteric site that are indispensable to the activity of
propionate.22 Small structural changes of the tetrahydroquino-
lones have shown to affect themode of action, ranging from pure
allosteric agonists tomodulators that either enhance the potency
of propionate (positive allosteric modulators, PAMs), reduce
the efficacy of propionate (negative allosteric modulators,
NAMs), or acting as both agonists on their own but also
enhance the potency of propionate (PAM agonists).
Herein, we present the results from a thorough examination of
the structure−activity relationships (SAR) within this com-
pound series and further characterize bioavailability and
pharmacokinetic properties of the most promising analogues.
Moreover, we use a key compound to demonstrate the
functional activity of FFA3 in cells of murine dorsal root ganglia.
■ SYNTHESIS
The tetrahydroquinolone target compounds were typically
synthesized from the appropriate 3-ketoamide, aldehyde, and
3-aminoenone using the Hantzsch dihydropyridine synthesis
(Scheme 1). Heating at 80 °C in i-PrOH for up to 5 days
generally gave the best outcome, with longer reaction times for
more hindered substrates.29 Microwave heating or synthesis
from 3-ketoamide, aldehyde, 1,3-dione, and ammonia provided
the product in shorter time but at the expense of lower yield and
purity. The 3-ketoamide substrates were most conveniently
accessed by heating of the appropriate aniline in neat methyl
acetoacetate. These intermediates were also synthesized by
heating of the aniline with 2,2,6-trimethyl-4H-1,3-dioxin-4-one
or in the presence of Lewis acid catalysts but generally with an
inferior outcome. The preferred route to the typical tetrahy-
droquinolone is shown in Scheme 1.
■ RESULTS AND DISCUSSION
The ligands were initially screened in a human FFA3-dependent
[35S]GTPγS binding assay as this assay reflects receptor-
mediated activation of Gi/o proteins and is known to generally
correlate well with ligand affinity.30 Analogues of particular
interest were tested further in a cAMP inhibition assay as this is
an important downstream effect of Gi-activation. The latter was
applied as a standard assay because of higher reproducibility. It is
furthermore performed in whole cells, is more downstream,
includes G protein signal amplification, and therefore better
reflects a more natural ligand−receptor response. Because the
series binds to an allosteric site on FFA3,22 selected compounds
were also tested together with a fixed submaximal concentration
of the SCFA propionate to investigate potential allosteric effects
on orthosteric agonist function.
Tetrahydroquinolones 1 and 2 were disclosed by Arena
Pharmaceuticals in 2006.23 We resynthesized these compounds,
confirming FFA3 agonist activity in the lowmicromolar range.22
2-Furyl derivative 1 showed agonist activity with approximately
2-fold higher potency than 3-furyl derivative 2 in the GTPγS
assay (Table 1).
Table 1. Initial SAR Investigations of 1,4,7,8-
Tetrahydroquinol-5-one-3-carboxamides
aMean of ≥3 independent experiments ± standard error. Efficacy
(Emax) is relative to maximal response of propionate.
bcAMP assay in
the presence of 1 μM propionate. cCalculated by ChemDraw
Professional version 16. dPreviously published.21,22 eNo response.
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://dx.doi.org/10.1021/acs.jmedchem.9b02036
J. Med. Chem. 2020, 63, 3577−3595
3578
Replacing the 2-furyl with phenyl (3) led to significant
deterioration of potency, whereas 2-thienyl (4), a group with a
size and polarity that more closely resembles phenyl than furyl,
largely preserved potency in the GTPγS assay.
The analogue with 2-bromophenyl (5) was previously
characterized and found to be inactive alone but to act as a
PAM of propionate, implying that 5 binds to FFA3 but is unable
to activate the receptor directly.22 Introducing bromosubstitu-
ents in the 3- (6) or 4-position (7) of phenyl derivative 3
regainedmost of the activity relative to 2-furyl derivative 1 in the
GTPγS assay, whereas the potency was essentially constant for
3−4 and 6−7 in the cAMP assay. Analogues with 3- (8) and 4-
trifluoromethyl (9) and 4-methyl (10) substituents were full
agonists with potencies similar to or lower than that of the
unsubstituted 3, whilst extension to 4-ethyl (11) eroded
potency.
Replacement of o-tolyl by phenyl (12) gave a >3-fold drop in
potency, whereasm-tolyl (13) or p-tolyl (14) resulted in a more
moderate drop, indicating the ortho-position as the most
interesting. Introduction of methoxy (15) further eroded
potency in the GTPγS binding assay but retained potency in
the cAMP inhibition assay. The 2,5-dichloro-substituted
AR420626 (16) also originates from Arena Pharmaceuticals
and has been described as a tool compound in the literature and
characterized by us.22,24,25 Like 1, this compound exhibited only
moderate potency in the GTPγS assay22 but is an order of
magnitude more potent in the cAMP assay. It thus represents
one of the most potent compounds but is also known to have
poor solubility.
We also wished to explore aliphatic R1 groups, and we were
pleased to find that isobutyl (17) behaved as an FFA3 agonist
with a potency similar to that of 1 in the [35S]GTPγS binding
assay. Introducing 2,3-dimethyl (18), 2-iodo (19), 2-chloro
(20), or 2,6-difluorophenyl (21) on the R2 phenyl while keeping
R1 as isobutyl produced active compounds with potencies
comparable to that of 17, with 20 representing an improvement
in the cAMP but not in the GTPγS assay. In general, results from
the cAMP assay corresponded satisfactorily with the GTPγS
data, although some of the compounds deviated considerably.
Notably, increased potency of 10-, 14-, and 50-fold was observed
for 2, 3, and 15, respectively. In contrast, only 17 and 18
exhibited a lower potency of 5- and 2-fold, respectively. On the
other hand, together with 1 μM propionate, 17 exhibited a
potency that was equal with 1 (with or without propionate). As
the cAMP assay is more downstream and showed a
reproducibility that was at least as good as the GTPγS assay,
this was chosen as the primary assay for the remaining
compounds.
We next turned our attention to the other parts of the
structure (Table 2). An extension of the ortho-methyl at the
dihydropyridine to ethyl (22) led to an order of magnitude
decrease of potency while a phenyl (23) produced a completely
inactive compound. Oxidation of the dihydropyridine to
pyridine (24) also produced an inactive compound, perhaps
unsurprisingly because this compound represents substantial
structural changes.
Using 17 as a starting point, opening of the cyclohexanone
and formation of a phenone (25) or methyl ester (26) both
produced compounds that were inactive (pEC50 < 4) alone but
Scheme 1. General Synthetic Route for Tetrahydroquinolone Ligands
Table 2. Scaffold Exploration of Furyl and Isobutyl Analogues
aMean of ≥3 independent experiments ± standard error. Efficacy (Emax) is relative to maximal response of propionate. bcAMP assay in the
presence of 1 μM propionate. cNo response. dGTPγS assay.
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26 acted as PAM with propionate, indicating that some larger
changes in the structure also produced compounds with affinity
for FFA3. Introduction of a nitrile (27) produced a compound
that was active alone, albeit with low potency, but that was
substantially potentiated by the presence of propionate. We also
wished to explore the significance of the ketone; however, all
attempts to reduce the cyclohexanone carbonyl or derivatize, for
example, to form oximes, were unsuccessful, partly due to low
electrophilicity due to stabilization by conjugation to the
enamine of the dihydropyridine system and partly due to
instability of products.
Replacement of the anilide part by a methyl ester (28) or a
phenone (29) produced compounds that also were inactive
alone but exhibited PAM properties. Introduction of a
carboxylic acid in this position produced a compound that
could not be characterized or tested due to insufficient solubility.
We next reverted to the R1 group to further explore aliphatic
substituents (Table 3). Introduction of sec-butyl (30) resulted in
a compound with very similar properties to isobutyl 17. The
sterically more well-defined cyclohexyl (31) gave marginally
increased potency which could be a result of a hydrophobic
effect. Surprisingly, the slightly smaller cyclopentyl (32)
increased potency 20-fold to 288 nM. Cyclopropyl (33)
maintained good potency at 600 nMwith an order of magnitude
reduced lipophilicity. A series of n-alkyls from ethyl to pentyl
(34−37) resulted in agonists with micromolar potency, with
propyl (35) and butyl (36) being the most potent and the
shorter ethyl (34) the least potent. Further extension with
phenethyl (38), styryl (39), and pyrazolylethyl (40) continued
this trend with pEC50 values <5, interestingly, with the less
lipophilic 40 exhibiting the highest potency of the three. All
compound were full agonists.
Identification of the cyclopentyl as the most potent aliphatic
substituent motivated another venture into similarly sized
aromatic substituents. N-Methyl-2-pyrazole (41) was a low-
potency compound, in line with ortho-substituted phenyls such
as 5. Furyls and thienyls with small substituents resulted in better
potency, with 5-bromo-2-furyl (44) and 2-benzofuryl (45) as
the most potent. The lower potency of 3-benzothienyl 46 is
likely due to the positioning of the benzene ring.
In an attempt to increase aqueous solubility by decreasing
lipophilicity, the 2-furyl of 16 was replaced by 2-thiazolyl (47),
5-thiazolyl (48), and 4-thiazolyl (49) (Table 3). This strategy
failed, as the solubility dropped from 5 to below 2 μM for the
thiazolyl analogues in a kinetic solubility assay, although the
potency was only slightly decreased for 47 (Table 4). Also, even
though clogP of 47−49 indicated an order of magnitude
improvement of lipophilicity relative to 16 (log D7.4 = 3.19),
measured log D7.4 revealed similar or increased lipophilicity.
Replacement by 4-oxazolyl (50) improved solubility >10-fold
but had a detrimental effect on potency. On the other hand, 2-
oxazolyl (51) improved potency but reduced solubility to 1 μM.
Table 3. SAR Exploration of Aliphatic and Heterocyclic Analogues
aMean of ≥3 independent experiments ± standard error. Efficacy (Emax) is relative to maximal response of propionate.
bcAMP assay in the
presence of 1 μM propionate. cCalculated by ChemDraw Professional version 16. dPreviously published.31
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With a focus on solving the solubility problem, we returned to
the aliphatic substituents aiming to incorporate a positive
charge. Unfortunately, both small polar and larger, lipophilic
amine substituents (52−54) produced inactive compounds.
Analogues with negatively charged carboxylate groups in the
same position (not shown) were also explored but were
completely inactive. Boc-protected intermediates (55−56)
were tested and found to be inactive alone. 52−55 were also
inactive in the presence of 3 μM propionate and were therefore
also not PAMs. However, 56, representing the compound with
the largest R1 substituent explored in this study, turned out to be
a NAM, effectively inhibiting receptor signaling at 30 μM
concentration (Figure 1). This is in line with previous
compounds characterized as FFA3 NAMs, where R1 was 3- or
4-phenoxyphenyl and substantially larger than other R1-groups
explored in the series. Thus, a larger R1 increases the chance of
finding a NAM or antagonist.
We reasoned that the generally poor physicochemical
properties of the 2,5-dichlorophenyl compounds are worsened
with aromatic or larger, lipophilic R1-groups. With the failure of
positively charged R1 groups to produce FFA3 agonists, we
therefore proceeded with exploration of smaller neutral groups.
The combination of n-propyl with 2,5-dichlorophenyl (57)
indeed produced a compound with similar potency to 16 but 6-
fold increased solubility (Table 5). Hoping to further increase
solubility, we next investigated the requirements of chlorinated
R2-groups in relation to potency. The 2-chloro (58) or 5-chloro
Table 4. SAR Exploration of 2,5-Dichloro Analogues
aMean of ≥3 independent experiments ± standard error. Efficacy
(Emax) is relative to maximal response of propionate.
bCalculated by
ChemDraw Professional version 16. cKinetic solubility at 25 °C in
phosphate buffered saline pH 7.4 (PBS7.4).
dNo response.
Figure 1. NAM 56 in the cAMP assay. (a) Concentration−response
curves for propionate (C3) alone or together with 30 μM 52−56. (b)
Concentration−response curves for C3 and 52−56 with 3 μM C3. (c)
Concentration−response curves for C3 alone and with increasing
concentrations of 56 (from 300 nM to 30 μM). Data represent the
mean of three independent experiments and is normalized to forskolin.
Table 5. SAR of Neutral Aliphatic R1 and Chlorinated R2
aMean of ≥3 independent experiments ± standard error. Efficacy
(Emax) is relative to maximal response of propionate.
bCalculated by
ChemDraw Professional version 16. dNo response.
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(59) substituents alone were accompanied by 4−5-fold
increased solubility compared to 57 but reduced potency
down to a level similar to o-tolyl (35, Table 3). The solubility of
35 was 199 μM and its log D7.4 was 2.64 and thus favorable
compared to all chlorinated compounds and comparable with 1
(190 μM solubility, log D7.4 2.05). A tendency toward higher
potency for 58 indicated that the 2-chloro is more important
than the 5-chloro, in line with observations for methyl
substituents (cf. 1, 13, 14, Table 1). In an attempt to regain
potency but keep the solubility properties, the 5-chloro of 57
was replaced by methyl (60) or methoxy (61). This indeed
resulted in compounds with solubilities similar to the other
monochlorinated compounds, but the potency was also similar
or only marginally improved. Chemical stability was also tested,
and all compounds (58−61) were completely recovered after 1
week at 37 °C in PBS. Finally, revisiting small aliphatic cycles,
cyclopropyl (62) partly regained and cyclopentyl (63) fully
regained the potency of the 2-furyl analogue 16, but with similar
or only moderately increased solubility. Compounds 62 and 63
were also tested in the cAMP assay together with 1 μM
propionate but did not reveal significant PAM effects. Overall, of
the compounds tested as PAMs, none with pEC50 > 6 showed
significantly enhanced potency in the presence of propionate.
To identify the most active enantiomer, racemic 1 was
resolved by chiral HPLC and crystallized. The single crystal X-
ray structures for one enantiomer (Figure 2) along with that of
the racemate (Figure S1) were determined. The absolute
configuration of the most active enantiomer (R)-1 was
determined by anomalous dispersion effects with a Flack
parameter of 0.04(12). However, the assignment must be
viewed with some caution because of the high standard
deviation in the Flack parameter. Crystal packing is influenced
by the presence of a single or both enantiomers in the lattices of
(R)-1 and (R,S)-1, respectively. Both structures show that the
strongest intermolecular interaction between molecules is the
H-bonding between the cyclic carbonyl (O1) and the amineNH
group (N1) of the adjacent molecule (Figure S2). These H-
bonds link themolecules in ribbons approximately parallel to the
a- and c-axis in the structures of (R)-1 and (R,S)-1, respectively
(Figures S5 and S2). The ribbons stack with the 2-furyl rings
located on the same side of every molecule in (R)-1 (Figure S6).
In (R,S)-1, they are alternating in the up and down positions in
accordance with theH-bonded ribbons comprising alternatingR
and S enantiomers (Figure S3).
The previously published compound 1 was not affected by
mutation of either R185A or R258A in the orthosteric binding
site, and the compounds were therefore believed to be allosteric
modulators. In the search for the potential allosteric binding site,
we mutated a third arginine residue in a neighboring site
(R71A); however, this did not affect the potency of 1. After the
Figure 2. Identification of the most potent enantiomer. (a) cAMP data for (R)-1 and (S)-1, data are mean of≥3 independent experiments± standard
error. Structure and numbering scheme of one of the two molecules (molecule A) in the asymmetric unit of (R)-1.
Figure 3. Proposed allosteric binding site in a homology model of hFFA3 in complex with (R)-1. (a) Full receptor marked with the orthosteric binding
site and potential allosteric binding site. (b) Overlay of 7 out of 10 docking poses. (c) Binding pocket surface. (d) Binding pose highlighting Q131.
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publication of the FFA1 crystal structure in complex with an
allosteric agonist located in the TM region close to the
intracellular site,32 a homologymodel of hFFA3 was constructed
using Modeller. The model revealed a similar potential binding
site on FFA3 and initial docking studies of (R)-1 indicated three
amino acids that might be involved in binding (Figure 3a).
Mutation of E112A and R126A did not affect the potency of
(R)-1 or propionate, whereas Q131A significantly reduced the
potency of (R)-1 (>3-fold, p < 0.001) but did not affect the
potency of propionate. Thus, additional docking of (R)-1 in this
site were performed to find poses where Q131, but not R126,
show a central role in binding. Seven out of 10 poses showed a
hydrogen bond interaction between Q131 and either the amide
carbonyl or the ketone without any constraints used and only
one of the poses showed an additional hydrogen bonding to
R126 (Figure 3b). The narrow binding cavity around the core
scaffold is in agreement with the restrained SAR observed for
this series and the furan moiety pointing out of the binding
cavity might explain the flexibility in substituents at this site
(Figure 3c,d). Although Q131A impacts the potency of (R)-1
with high significance, the magnitude of the effect is lower than
what would be generally expected for the removal of a hydrogen
bond interaction; thus, additional studies are required to
confirm the proposed binding site.
With several compounds with improved properties in hand,
we wished to investigate the suitability of the compounds as
tools for in vivo studies in rodents. Because of the moderate
potency and low solubility associated with this series, it has been
presumed that they are poorly suited as in vivo tools. A basic
requirement is preserved activity on the relevant species
orthologues, which generally has been observed to be low
within the free fatty acid receptor group.19 We confirmed that
propionate maintained potency between human and rodent
species. 1 and 16 both lost 3−10-fold potency from human to
rodent species (1 pEC50 = 5.87± 0.07 on rFFA3, 5.42± 0.04 on
mFFA3; 16 pEC50 = 6.34 ± 0.04 on rFFA3, 5.88 ± 0.05 on
mFFA3), whereas 63 now tended toward the highest potency on
the rodent orthologues (pEC50 = 6.39± 0.03 on rFFA3; pEC50 =
5.96 ± 0.04 on mFFA3).
We next investigated the chemical stability of the compounds
and stability toward liver microsomes. Representative com-
pounds were shaken in PBS at pH 7.4. Apart from some that
precipitated, all compounds were quantitatively recovered after
1 week. On the other hand, the tested compounds exhibited
varying stability towards mouse liver microsomes (MLM, Table
6). In the one end, 1 and 63 showed good stability, comparable
with the propranolol reference compound (61%). In the other
end, only 1−2% was recovered of 16, 47, 57, and 62. The
remaining compounds were in the intermediate range. Apart
from a generally higher stability of the o-tolyl compounds 1 and
35 than the remaining 2,5-dichlorophenyl compounds, it was
difficult to see a clear relationship between structural or
physicochemical properties and microsomal stability.
Based on the results so far, 63 appeared as a good compromise
between the properties of 1 and 16, and 57 represented a good
compromise between potency and solubility. We therefore
selected these four compounds for pharmacokinetic studies in
mice. Although the microsomal data for at least 16 and 57
indicated that these compounds would have a fast clearing, we
decided to run the pharmacokinetic study using the same time
frame for all compounds. Overall, the four compounds had
surprisingly favorable PK properties and especially 1, 16, and 63
showed high bioavailability. Compound 1 exhibited the longest
half-life, approximately an hour after iv dosing, and the lowest
clearance, whereas 16 showed a half-life of 20 min. 63 was
somewhat in between the two, and 57 had the shortest iv half-
life. Half-life after oral dosing was satisfactory for all compounds.
1, 16, 57, and 63 were counterscreened on the related FFA
receptors FFA1 and FFA2, the more distant FFA receptors
FFA4 and GPR84, and the L-type calcium ion channels, a target
for related dihydropyridine ligands. No significant activity was
detected at any of the receptors at 10 μM concentration (see
Supporting Information).
Because of its good compromise between solubility and
potency (EC50 = 2 μMat mFFA3 vs 30 μM for propionate in the
GTPγS assay), 57 was considered for further in vitro studies. To
further ensure the suitability of 57 as a tool compound for in
vitro studies, the chemical stability was also evaluated in
dimethyl sulfoxide (DMSO). An NMR sample was stored at 4
°C, and recordings after 1 and 30 days showed complete
stability. A sample stored at rt (not protected from light) was
fully stable for 7 days, whereas minor decomposition was
detected after 30 days (see Supporting Information).
Thus, 57 was selected for studies in cells from dorsal root
ganglia (DRGs) isolated from wild-type and FFA3 KO mice.
Addition of 57 (5 μM) gave a large elevation in intracellular
calcium levels in wild type but not FFA3 KO cells, indicating a
FFA3-specific effect of 57 on DRG cells (Figure 4). These
results suggest, in line with previous studies,17,18 a key role for
FFA3 in mediating effects for SCFAs from the gut microbiome
within the peripheral nervous system. They furthermore for the
first time demonstrate a pharmacological intervention at
ganglionic FFA3, that 57 is able to evoke a response with high
selectivity and that ganglionic FFA3 has potential as a
therapeutic target for pain and metabolic disorders. Further
Table 6. In Vitro Stability and in Vivo Pharmacokinetic Properties of Selected Compounds in Mice
iv dosing (5 mg/kg) po dosing (10 mg/kg)
cAMP
pEC50
a
aq. sol.
(μM)a
log
D7.4
a
MLM
(%)b
t1/2
(min)
Vd
(mL/kg)
CLtotal
(mL/min/kg)
t1/2
(min)
tmax
(min)
cmax
(ng/mL)
AUCinf
(ng.min/mL)
F
(%)
1 6.28 190 2.05 52 62.2 759 8.45 89.7 15 7470 865 000 73
16 6.89 5 3.19 1 22.3 629 19.6 60.8 30 5740 423 000 88
35 5.92 199 2.64 23
47 6.60 1 3.39 2
51 6.72 1 2.59 12
57 6.84 33 4.25 1 11.4 1150 70.3 63.5 30 561 33 800 36
62 6.60 5 3.73 1
63 6.79 9 >4.3 41 37.8 1110 20.3 51.8 15 3800 325 000 66
aMost data are replicated from Tables 1 and 3−5 (for SEM and Emax, see these tables). bRemaining after 40 min incubation with MLMs.
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studies of the role of FFA3 in dorsal root ganglions using 57 as a
tool compound are in progress.
■ CONCLUSIONS
We have performed an extensive SAR investigation around a
series of 1,4,7,8-tetrahydroquinol-5-one FFA3 allosteric modu-
lators that has led to the identification of key structural parts
required for inducing effects on FFA3 and parts where
modifications are permitted. The studies revealed that the
aromatic substituents at the 4-position (referred to as R1) can be
replaced by small aliphatic substituents with fully preserved
potency. Extension of the R1-group leads to loss of agonist
activity but may produce antagonists or NAMs. The 2,5-
dichlorophenyl at the amide (R2) has a beneficial effect on
potency but a detrimental effect on solubility. The combination
of N-2,5-dichlorophenyl with a smaller aliphatic substituent in
the 4-position on the tetrahydroquinol-5-one resulted in
compounds with preserved potency and improved solubility.
The most potent enantiomer was found to have the (R)-
configuration. We have for the first time evaluated the in vitro
solubility, lipophilicity, and metabolic stability and in vivo
pharmacokinetic properties of members of this compound
series. Despite largely suboptimal result from in vitro studies, the
compounds overall demonstrated surprisingly favorable in vivo
pharmacokinetic properties. Compound 63 was found to have
well preserved potency on rodent orthologues, good stability
toward MLMs, and favorable PK properties for use as an in vivo
tool compound. The previously characterized agonists 1 and 16
were also found to have surprisingly favorable PK profiles,
although the former suffers from moderate potency and the
latter from low solubility. Compound 57 was found to have
sufficiently good aqueous solubility and good potency but
showed the least favorable PK properties of the studied
compounds; thus this is the preferred compound for in vitro
but not in vivo studies. Studies of 57 in isolated DRGs
demonstrated potent and FFA3-specific calcium mobilization in
DRG cells. The study shows that compounds from this series, in
the absence of highly potent FFA3 agonists, have merits as both
in vitro and in vivo research tools.
■ EXPERIMENTAL SECTION
All commercial starting materials and solvents were used without
further purification, unless otherwise stated. Chemicals were obtained
from Sigma-Aldrich, except 3-oxo-N-(o-tolyl)butanamide (Fluoro-
chem), 2′,5′-dichloroacetoacetanilide (Alfa Aesar), oxazole-2-carbox-
aldehyde (Combi-Blocks), and 2-(dimethylamino)acetaldehyde
(Combi-Blocks). THF was freshly distilled from sodium/benzophe-
none. DCM was freshly distilled and stored over 4 Å sieves. TLC was
performed on TLC Silica gel 60 F254 plates and visualized at 254 nm or
by staining with ninhydrin, phosphomolybdic acid, or KMnO4.
Petroleum ether refers to alkanes with bp 60−80 °C. Purification by
flash chromatography was carried out using silica gel 60 (0.040−0.063
mm, Merck) or in prepacked columns on a Reveleris X2. 1H and 13C
NMR spectra were recorded at 400 (or 500) and 101 MHz at 300 K.
Spectra were calibrated relative to residual solvent peaks: 1H NMR
(CDCl3): 7.26 ppm;
13C NMR (CDCl3): 77.16 ppm;
1H NMR
(DMSO-d6): 2.50 ppm;
13C NMR (DMSO-d6): 39.52 ppm;
1H NMR
(CD3OD): 3.31 ppm;
13C NMR (CD3OD): 49.00 ppm;
1H NMR
(acetone-d6): 2.05 ppm;
13CNMR (acetone-d6): 29.84 ppm. Purity was
determined by HPLC and confirmed by inspection of NMR spectra
(1H and 13C NMR). HPLC analysis was performed using a Dionex 120
C18 column (5 μm, 4.6 × 150 mm) or Gemini C18 column (5 μm, 4.6
× 150 mm); flow: 1 mL/min; 10% MeCN in water (0−1 min), 10−
100% MeCN in water (1−10 min), and 100% MeCN (10−15 min),
with both solvents containing 0.1% formic acid as modifier; UV
detection at 254 nm. Purification of enantiomers was performed on a
chiral LUX cellulose-1 column. High-resolution mass spectra (HRMS)
were recorded on a Bruker micrOTOF-Q II (ESI). None of the test
compounds showed patterns associated with PAINS or aggregators by
screening in Zinc (http://zinc15.docking.org/patterns/home/). All
test compounds were of ≥95% purity with the exception of 41 (82.1%)
and 46 (94.3%).
X-ray crystal diffraction data were collected at 100(2) K on a
Synergy, Dualflex, AtlasS2 diffractometer using CuKα radiation (λ =
1.54184 Å) and the CrysAlis PRO 1.171.38.43 suite. Using Olex2,33 the
structures were solved with the ShelXT34 structure solution program
using Intrinsic Phasing and refined with the ShelXL34 refinement
package using Least Squares minimization. All nonhydrogen atoms
were refined using anisotropic atomic displacement parameters, and
hydrogen atoms were inserted at calculated positions using a riding
model, except those belonging to the secondary amine and the amide
groups. These hydrogen atoms were located in different electron
density maps, and their positions were refined. The methyl group C22
in (R,S)-1 is disordered over both ortho positions on the aromatic ring,
and the occupancy was refined to 76%:24% occupancy. Crystal data for
(R,S)-1: C22H22N2O3 (M = 362.41 g/mol): monoclinic, space group
P21/c (no. 14), a = 17.6367(2) Å, b = 7.53560(10) Å, c = 14.3717(2) Å,
β = 111.5790(10)°, V = 1776.17(4) Å3, Z = 4, T = 100(2) K, μ(CuKα)
= 0.732 mm−1, Dcalc = 1.355 g/cm
3, 36 815 reflections were measured
(10.788° ≤ 2Θ ≤ 133.202°), and 3132 are unique (Rint = 0.0364, Rsigma
= 0.0139), which were used in all calculations. The final R1 was 0.0471
(I > 2σ(I)) and wR2 was 0.1318 (all data). Crystal data for (R)-1:
C22H22N2O3 (M = 362.41 g/mol): triclinic, space group P1 (no. 1), a =
7.1817(3) Å, b = 7.4711(3) Å, c = 16.6298(4) Å, α = 87.768(3)°, β =
87.408(3)°, γ = 87.615(3)°, V = 889.98(6) Å3, Z = 2, T = 100(2) K,
μ(CuKα) = 0.730 mm−1, Dcalc = 1.352 g/cm
3, 16 586 reflections were
measured (11.864° ≤ 2Θ ≤ 152.862°), and 6283 are unique (Rint =
0.0454, Rsigma = 0.0384), which were used in all calculations. The final
R1 was 0.0371 (I > 2σ(I)) and wR2 was 0.0952 (all data). Flack
parameter was 0.04(12). Further details of the X-ray diffraction data,
including bond lengths and angles, can be found in the Supporting
Information. CCDC 1905506 and 1905507 contain the supplementary
crystallographic data for (R,S)-1 and (R)-1, respectively. These data can
be obtained free of charge from the Cambridge Crystallographic Data
Centre via www.ccdc.cam.ac.uk/data_request/cif.
General Tetrahydroquinoline (THQ) Procedure. A vial was
charged with 3-aminocyclohex-2-en-1-one (1 equiv.), aldehyde (1−1.2
equiv.), 3-oxo-N-(o-tolyl)butanamide (1 equiv.), and isopropanol
(IPA) (5 mL/mmol). The vial was capped and heated to 80 °C for
1−5 days. Afterward, the reaction mixture was cooled to room
temperature, diluted with EtOAc, and concentrated on Celite before
purification by flash chromatography.
General THQ-II Procedure. AMW vial was charged with aldehyde
(1 equiv.), cyclohexane-1,3-dione (1 equiv.), 3-oxo-N-phenylbutana-
mide derivative (1 equiv.), and ammonium acetate (1 equiv.). The vial
was heated to 150 °C until gas evolution had ceased and the mixture
solidified. The residue was purified by flash column chromatography.
Figure 4. Compound 57 promotes FFA3-dependent elevation of
intracellular Ca2+ in cells dissociated from mouse dorsal root ganglia.
The arrow indicates addition of 57 (5 μM). Results are expressed as
relative fluorescence; WT (black): N = 3 (number of mice), n = 34
(number of cells) and KO (red): N = 3, n = 28.
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2-Methyl-5-oxo-4-phenyl-N-(o-tolyl)-1,4,5,6,7,8-hexahydro-
quinoline-3-carboxamide (3). Compound 3 was prepared from
benzaldehyde (144mg, 1.36mmol), 3-aminocyclohex-2-en-1-one (167
mg, 1.50 mmol), and 3-oxo-N-(o-tolyl)butanamide (287 mg, 1.50
mmol) according to the general THQ procedure to give 257 mg (51%)
of a yellow solid (tR = 10.43 min, purity 98.8% by HPLC) after
purification by flash chromatography (SiO2, EtOAc/petroleum ether,
1:1): 1H NMR (400 MHz, CDCl3) δ 7.77−7.68 (m, 1H), 7.52−7.43
(m, 2H), 7.31 (t, J = 7.0Hz, 2H), 7.21 (t, J = 6.8 Hz, 1H), 7.13 (t, J = 7.4
Hz, 1H), 7.06−7.00 (m, 1H), 7.00−6.92 (m, 2H), 6.60−6.41 (m, 1H),
5.04 (s, 1H), 2.40 (s, 3H), 2.37−2.23 (m, 4H), 1.98−1.75 (m, 2H),
1.61 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 195.6, 166.4, 150.2,
145.1, 141.8, 136.2, 130.4, 129.2, 128.8, 128.3, 127.4, 126.5, 124.7,
122.9, 112.4, 107.8, 37.5, 37.1, 27.5, 21.0, 18.9, 17.1; ESI-HRMS calcd
for C24H25N2O2 (M + H)
+ 373.1912; found, 373.1911.
2-Methyl-5-oxo-4-(thiophen-2-yl)-N-(o-tolyl)-1,4,5,6,7,8-
hexahydroquinoline-3-carboxamide (4). Compound 4 was
prepared from thiophene-2-carbaldehyde (84 μL, 0.90 mmol), 3-
aminocyclohex-2-en-1-one (100 mg, 0.90 mmol), and 3-oxo-N-(o-
tolyl)butanamide (172 mg, 0.90 mmol) according to the general
procedure THQ to give 132 mg (35%) of a red foam (tR = 10.30 min,
purity 99.5% by HPLC) after purification by flash chromatography
(SiO2, EtOAc/petroleum ether, 5:1): Rf = 0.19 (SiO2, EtOAc/
petroleum ether, 5:1); 1H NMR (CDCl3) δ 7.75 (d, J = 7.9 Hz, 1H),
7.42 (s, 1H), 7.31 (s, 1H), 7.16 (dd, J = 5.1, 1.1 Hz, 1H), 7.15−7.09 (m,
1H), 7.08−7.01 (m, 2H), 6.97 (td, J = 7.5, 0.9Hz, 1H), 6.91 (dd, J = 5.1,
3.5 Hz, 1H), 5.31 (s, 1H), 2.35 (s, 3H), 2.42−2.25 (m, 4H), 1.95−1.87
(m, 1H), 1.86−1.80 (m, 1H), 1.77 (s, 3H); 13CNMR (CDCl3) δ 195.5,
166.4, 151.0, 149.7, 142.5, 136.1, 130.5, 128.9, 127.2, 126.5, 125.3,
125.0, 124.7, 122.8, 111.5, 107.2, 36.9, 32.6, 27.1, 21.0, 18.6, 17.0. ESI-
HRMS cald for C22H22N2NaO2S (M + Na)
+ 401.1294; found,
401.1285.
4-(3-Bromophenyl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-
hexahydroquinoline-3-carboxamide (6). Compound 6 was
prepared from 3-bromobenzaldehyde (278 mg, 1.50 mmol), 3-
aminocyclohex-2-en-1-one (167 mg, 1.50 mmol), and 3-oxo-N-(o-
tolyl)butanamide (287 mg, 1.50 mmol) according to the general THQ
procedure to give 128 mg (19%) of a yellow solid (tR = 11.08 min,
purity 96.6% by HPLC) after purification by flash chromatography
(SiO2, EtOAc/petroleum ether, 1:1):
1H NMR (400 MHz, CDCl3) δ
7.71 (d, J = 8.1 Hz, 1H), 7.56 (br s, 1H), 7.44 (d, J = 7.7 Hz, 1H), 7.35
(d, J = 8.0 Hz, 1H), 7.21−7.10 (m, 2H), 7.09−7.03 (m, 1H), 7.03−6.95
(m, 1H), 6.91 (s, 1H), 6.65−6.46 (m, 1H), 5.02 (s, 1H), 2.39 (s, 3H),
2.44−2.24 (m, 4H), 2.00−1.77 (m, 2H), 1.71 (s, 3H); 13C NMR (101
MHz, CDCl3) δ 195.5, 166.2, 150.6, 147.5, 141.9, 136.0, 131.1, 130.7,
130.5, 128.9, 127.1, 126.6, 124.9, 123.4, 123.1, 111.7, 107.3, 37.4, 37.0,
27.5, 20.9, 19.0, 17.3; ESI-HRMS calcd for C24H24BrN2O2 (M + H)
+
451.1016; found, 451.1017.
4-(4-Bromophenyl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-
hexahydroquinoline-3-carboxamide (7). Compound 7 was
prepared from 4-bromobenzaldehyde (278 mg, 1.50 mmol), 3-
aminocyclohex-2-en-1-one (167 mg, 1.50 mmol), and 3-oxo-N-(o-
tolyl)butanamide (287 mg, 1.50 mmol) according to the general THQ
procedure to give 226 mg (33%) of a yellow solid (tR = 11.14 min,
purity 96.5% by HPLC) after purification by flash chromatography
(SiO2, EtOAc/petroleum ether, 1:1):
1H NMR (400 MHz, CDCl3) δ
7.70 (d, J = 7.9 Hz, 1H), 7.45−7.38 (m, 2H), 7.38−7.30 (m, 2H), 7.12
(t, J = 7.5 Hz, 1H), 7.09−7.00 (m, 1H), 7.00−6.93 (m, 1H), 6.90 (br s,
1H), 6.52 (br s, 1H), 5.01 (s, 1H), 2.38 (s, 3H), 2.46−2.25 (m, 4H),
1.98−1.76 (m, 2H), 1.71 (s, 3H), 13C NMR (101 MHz, CDCl3) δ
195.5, 166.1, 150.4, 144.1, 141.7, 136.0, 132.2, 130.5, 130.0, 128.8,
126.6, 124.8, 122.9, 121.2, 111.9, 107.4, 37.1, 37.0, 27.5, 21.0, 18.9,
17.2; ESI-HRMS calcd for C24H24BrN2O2 (M + H)
+ 451.1016; found,
451.1006.
2-Methyl-5-oxo-N-(o-tolyl)-4-(3-(trifluoromethyl)phenyl)-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (8). Compound
8 was prepared from 3-(trifluoromethyl)benzaldehyde (87 mg, 0.50
mmol), cyclohexane-1,3-dione (56 mg, 0.50 mmol), 3-oxo-N-(o-
tolyl)butanamide (96 mg, 0.50 mmol), and ammonium acetate (39 mg,
0.51) according to the general THQ-II procedure to give 105mg (48%)
of a yellow solid (tR = 11.18 min, purity 97.5% by HPLC) after
purification by flash chromatography (SiO2, EtOAc/petroleum ether,
1:1): 1H NMR (400 MHz, CDCl3) δ 7.72−7.67 (m, 3H), 7.52−7.40
(m, 2H), 7.17−7.10 (m, 1H), 7.08−7.02 (m, 1H), 7.02−6.94 (m, 1H),
6.85 (br s, 1H), 6.42 (br s, 1H), 5.14 (s, 1H), 2.40 (s, 3H), 2.47−2.25
(m, 4H), 2.00−1.78 (m, 2H), 1.65 (s, 3H); 13C NMR (101 MHz,
CDCl3) δ 195.5, 166.1, 150.6, 146.1, 141.8, 135.9, 131.9 (q, J = 1.1 Hz),
131.4 (q, J = 32.1 Hz), 130.5, 129.6, 128.9, 126.7, 125.0, 124.7 (q, J =
3.8 Hz), 124.21 (q, J = 272.5 Hz), 124.19 (q, J = 3.7 Hz), 123.1, 111.7,
107.3, 37.6, 37.0, 27.5, 20.9, 18.9, 17.1; ESI-HRMS calcd for
C25H24F3N2O2 (M + H)
+ 441.1784; found, 441.1795.
2-Methyl-5-oxo-N-(o-tolyl)-4-(4-(trifluoromethyl)phenyl)-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (9). Compound
9 was prepared from 4-(trifluoromethyl)benzaldehyde (87 mg, 0.50
mmol), cyclohexane-1,3-dione (56 mg, 0.50 mmol), 3-oxo-N-(o-
tolyl)butanamide (95 mg, 0.93 mmol), and ammonium acetate (39 mg,
0.51) according to the general THQ-II procedure to give 85 mg (39%)
of a yellow solid (tR = 11.23 min, purity 96.8% by HPLC) after
purification by flash chromatography (SiO2, EtOAc/petroleum ether,
1:1): 1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 8.0 Hz, 1H), 7.62−
7.53 (m, 4H), 7.13 (t, J = 7.6 Hz, 1H), 7.08−7.03 (m, 1H), 6.99 (t, J =
7.4 Hz, 1H), 6.86 (br s, 1H), 6.58 (br s, 1H), 5.12 (s, 1H), 2.37 (s, 3H),
2.45−2.24 (m, 4H), 1.97−1.77 (m, 2H), 1.67 (s, 3H); 13C NMR (101
MHz, CDCl3) δ 195.6, 166.2, 150.9, 149.1 (q, J = 0.6 Hz), 141.4, 135.8,
130.5, 129.5 (q, J = 32.4 Hz), 129.1, 128.6, 126.6, 126.0 (q, J = 3.7 Hz),
125.1, 124.2 (q, J = 271.8 Hz), 123.2, 111.5, 107.6, 37.7, 37.0, 27.5,
20.9, 18.8, 17.1; ESI-HRMS calcd for C25H23F3N2NaO2 (M + Na)
+
463.1604; found, 463.1622.
2-Methyl-5-oxo-N-(o-tolyl)-4-(p-tolyl)-1,4,5,6,7,8-hexahy-
droquinoline-3-carboxamide (10). Compound 10 was prepared
from 4-methylbenzaldehyde (112 mg, 0.93 mmol), cyclohexane-1,3-
dione (104 mg, 0.93 mmol), 3-oxo-N-(o-tolyl)butanamide (178 mg,
0.93 mmol), and ammonium acetate (72 mg, 0.93) according to the
general THQ-II procedure to give 254 mg (71%) of a yellow solid (tR =
10.92 min, purity 96.3% by HPLC) after purification by flash
chromatography (SiO2, EtOAc/petroleum ether, 1:1):
1H NMR (400
MHz, CDCl3) δ 7.73 (d, J = 8.0Hz, 1H), 7.36 (d, J = 8.0Hz, 2H), 7.16−
7.09 (m, 3H), 7.05−6.99 (m, 2H), 6.99−6.93 (m, 1H), 6.57 (br s, 1H),
4.99 (s, 1H), 2.38 (s, 3H), 2.41−2.24 (m, 4H), 2.29 (s, 3H), 1.92−1.73
(m, 2H), 1.65 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 195.6, 166.5,
150.2, 142.2, 141.7, 137.0, 136.2, 130.4, 129.9, 128.8, 128.2, 126.5,
124.6, 122.9, 112.5, 107.8, 37.1, 37.1, 27.5, 21.2, 21.0, 18.8, 17.1; ESI-
HRMS calcd for C25H27N2O2 (M + H)
+ 387.2067; found, 387.2070.
4-(4-Ethylphenyl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-
hexahydroquinoline-3-carboxamide (11). Compound 11 was
prepared from 4-ethylbenzaldehyde (134 mg, 1.00 mmol), cyclo-
hexane-1,3-dione (112 mg, 1.00 mmol), 3-oxo-N-(o-tolyl)butanamide
(191 mg, 1.00 mmol), and ammonium acetate (77 mg, 1.00 mmol)
according to the general THQ-II procedure to give 77 mg (19%) of a
yellow solid (tR = 11.44 min, purity 95.0% by HPLC) after purification
by flash chromatography (SiO2, EtOAc/petroleum ether, 1:1):
1H
NMR (400MHz, CDCl3) δ 7.75 (d, J = 7.9Hz, 1H), 7.39 (d, J = 8.1Hz,
2H), 7.18−7.09 (m, 3H), 7.04−6.99 (m, 2H), 6.98−6.92 (m, 1H), 6.57
(br s, 1H), 4.99 (s, 1H), 2.59 (q, J = 7.6 Hz, 2H), 2.37 (s, 3H), 2.41−
2.24 (m, 4H), 1.92−1.75 (m, 2H), 1.58 (s, 3H), 1.19 (t, J = 7.6 Hz,
3H); 13C NMR (101 MHz, CDCl3) δ 195.6, 166.5, 150.2, 143.5, 142.5,
141.7, 136.3, 130.4, 128.7, 128.6, 128.3, 126.5, 124.5, 122.8, 112.5,
107.9, 37.1, 28.6, 27.5, 20.9, 18.8, 17.0, 15.8; ESI-HRMS calcd for
C26H29N2O2 (M + H)
+ 401.2224; found, 401.2241.
4-(Furan-2-yl)-2-methyl-5-oxo-N-(m-tolyl)-1,4,5,6,7,8-hexa-
hydroquinoline-3-carboxamide (13). 2,2,6-Trimethyl-4H-1,3-di-
oxin-4-one (711 mg, 5.0 mmol) and m-toluidine (536 mg, 5.0 mmol)
were dissolved in toluene (1 mL) and heated to 110 °C for 7 h. The
reaction was cooled to room temperature, concentrated, and filtered
through a small silica plug (EtOAc/petroleum ether, 1:4), and the
crude product of 3-oxo-N-(m-tolyl)butanamide was used directly in the
next step.
Compound 13 was prepared from furan-2-carbaldehyde (192 mg,
2.00 mmol), 3-aminocyclohex-2-en-1-one (222 mg, 2.00 mmol), and 3-
oxo-N-(m-tolyl)butanamide (382 mg, 2.00 mmol) according to the
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general procedure THQ to give 173 mg (24%) of a brown solid (tR =
10.26 min, purity 98.3% by HPLC) after purification by flash
chromatography (SiO2, EtOAc/petroleum ether, 1:1):
1H NMR (400
MHz, CDCl3) δ 7.87 (br s, 1H), 7.36−7.30 (m, 2H), 7.19−7.14 (m,
2H), 6.91−6.85 (m, 1H), 6.36 (br s, 1H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H),
6.14 (d, J = 3.2 Hz, 1H), 5.10 (s, 1H), 2.50−2.40 (m, 3H), 2.40−2.32
(m, 1H), 2.32 (s, 6H), 2.04−1.92 (m, 2H); 13C NMR (101 MHz,
CDCl3) δ 195.4, 166.1, 157.1, 151.4, 142.2, 142.1, 138.9, 138.4, 128.8,
125.0, 120.9, 117.3, 110.8, 108.8, 106.1, 105.8, 37.0, 31.2, 27.6, 21.6,
21.2, 19.2; ESI-HRMS calcd for C22H23N2O3 (M + H)
+ 363.1703;
found, 363.1694.
4-(Furan-2-yl)-2-methyl-5-oxo-N-(p-tolyl)-1,4,5,6,7,8-hexa-
hydroquinoline-3-carboxamide (14). 2,2,6-Trimethyl-4H-1,3-di-
oxin-4-one (1422 mg, 10.0 mmol) and p-toluidine (1072 mg, 10.0
mmol) were dissolved in toluene (2 mL) and heated to 110 °C for 6 h.
The reaction was cooled to room temperature and concentrated, and
the residue was purified by flash chromatography (SiO2, EtOAc/
petroleum ether, 1:4) to give 1456 mg (76%) of 3-oxo-N-(p-
tolyl)butanamide as a light brown solid that was used directly in the
next step.
Compound 14 was prepared from furan-2-carbaldehyde (192 mg,
2.00 mmol), 3-aminocyclohex-2-en-1-one (222mg, 2.00 mmol), and 3-
oxo-N-(p-tolyl)butanamide (382 mg, 2.00 mmol) according to the
general procedure THQ to give 292 mg (40%) of a brown solid (tR =
10.23 min, purity 98.3% by HPLC) after purification by flash
chromatography (SiO2, EtOAc/petroleum ether, 1:1):
1H NMR (400
MHz, CDCl3) δ 7.86 (br s, 1H), 7.34−7.28 (m, 3H), 7.12−7.05 (m,
2H), 6.43 (br s, 1H), 6.29 (dd, J = 3.2, 1.9 Hz, 1H), 6.13 (d, J = 3.2 Hz,
1H), 5.10 (s, 1H), 2.50−2.40 (m, 3H), 2.40−2.32 (m, 1H), 2.30 (s,
3H), 2.29 (s, 3H), 2.03−1.88 (m, 2H); 13CNMR (101MHz, CDCl3) δ
195.4, 166.1, 157.2, 151.5, 142.0, 135.9, 133.7, 129.5, 120.3, 110.8,
108.7, 106.0, 105.8, 37.0, 31.2, 27.6, 21.2, 21.0, 19.1; ESI-HRMS calcd
for C22H22N2NaO3 (M + Na)
+ 385.1523; found, 385.1528.
4-(Furan-2-yl)-N-(2-methoxyphenyl)-2-methyl-5-oxo-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (15). 2,2,6-Tri-
methyl-4H-1,3-dioxin-4-one (711mg, 5.0 mmol) and 2-methoxyaniline
(616mg, 5.0 mmol) were dissolved in dry toluene (1mL) and heated to
110 °C for 6 h. The reaction was cooled to room temperature and
filtrated. The solid was washed with ice cold toluene to give 268 mg
(26%) of N-(2-methoxyphenyl)-3-oxobutanamide as a light brown
solid that was used directly in the next step.
Compound 15 was prepared from furan-2-carbaldehyde (48 mg,
0.50 mmol), cyclohexane-1,3-dione (56 mg, 0.50 mmol), N-(2-
methoxyphenyl)-3-oxobutanamide (104 mg, 0.50 mmol), and
ammonium acetate (39 mg, 0.51) according to the general procedure
THQ-II to give 32 mg (17%) of a yellow solid (tR = 10.27 min, purity
97.7% by HPLC) after purification by flash chromatography (SiO2,
EtOAc/petroleum ether, 1:1): 1H NMR (400 MHz, CDCl3) δ 8.33 (br
s, 1H), 8.30 (dd, J = 8.0, 1.5 Hz, 1H), 7.33−7.28 (m, 1H), 6.99 (td, J =
7.8, 1.6 Hz, 1H), 6.91 (td, J = 7.8, 1.2 Hz, 1H), 6.82 (dd, J = 8.0, 1.1 Hz,
1H), 6.46 (br s, 1H), 6.29 (dd, J = 3.1, 1.9 Hz, 1H), 6.19 (d, J = 3.1 Hz,
1H), 5.13 (s, 1H), 3.78 (s, 3H), 2.50−2.38 (m, 3H), 2.37−2.26 (m,
1H), 2.33 (s, 3H), 2.06−1.88 (m, 2H); 13CNMR (101MHz, CDCl3) δ
195.4, 166.1, 156.7, 151.4, 148.4, 142.1, 142.0, 128.3, 123.5, 121.0,
120.1, 110.4, 110.1, 109.0, 106.2, 106.1, 55.7, 37.0, 31.2, 27.6, 21.2,
19.1; ESI-HRMS calcd for C22H23N2O4 (M + H)
+ 379.1652; found,
379.1671.
4-Isobutyl-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahy-
droquinoline-3-carboxamide (17). Compound 17 was prepared
from 3-aminocyclohex-2-en-1-one (111 mg, 1.00 mmol), 3-methyl-
butanal (110 μL, 1.02 mmol), and 3-oxo-N-(o-tolyl)butanamide (191
mg, 1.00mmol) according to the general procedure THQ to give 96mg
(27%) of a pale yellow solid (tR = 10.74 min, purity 98.0% by HPLC)
after purification by flash chromatography (SiO2, EtOAc):
1H NMR
(400 MHz, DMSO-d6) δ 9.10 (s, 1H), 8.58 (s, 1H), 7.31−7.03 (m,
4H), 3.83 (t, J = 6.3 Hz, 1H), 2.46−2.14 (m, 7H), 2.06 (s, 3H), 1.98−
1.55 (m, 3H), 1.33−0.96 (m, 2H), 0.83 (dd, J = 6.5, 1.9 Hz, 6H); 13C
NMR (101MHz, DMSO-d6) δ 194.1, 168.2, 152.7, 136.8, 134.2, 132.7,
130.1, 125.7, 125.6, 125.0, 111.5, 109.4, 47.0, 36.9, 29.6, 26.5, 23.6,
23.4, 23.0, 20.9, 18.1, 17.0; ESI-HRMS calcd for C22H28N2NaO2 (M +
Na)+ 375.2043; found, 375.2052.
N-(2,3-Dimethylphenyl)-4-isobutyl-2-methyl-5-oxo-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (18). A dry flask
was charged with 2,3-dimethylaniline (0.12 mL, 1.0 mmol), 2,2,6-
trimethyl-4H-1,3-dioxin-4-one (0.13 mL, 1.00 mmol), and toluene (0.2
mL) and heated to reflux under argon for 5 h. Afterward, the reaction
was cooled to room temperature and concentrated in vacuo. The
residue was purified by flash chromatography (SiO2, EtOAc/petroleum
ether, 1:1) to give 138 mg (67%) of N-(2,3-dimethylphenyl)-3-
oxobutanamide as a beige solid: Rf = 0.20 (SiO2, EtOAc/petroleum
ether, 1:1); 1H NMR (400 MHz, CDCl3) δ 9.01 (br s, 1H), 7.55 (d, J =
8.0 Hz, 1H), 7.08 (t, J = 7.8 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 3.60 (s,
2H), 2.31 (s, 3H), 2.29 (s, 3H), 2.18 (s, 3H); 13C NMR (101 MHz,
CDCl3) δ 205.7, 163.9, 137.5, 135.3, 128.9, 127.3, 125.9, 121.6, 49.5,
31.3, 20.7, 13.8; ESI-HRMS calcd for C12H15NNaO2 (M + Na
+)
228.0995; found, 228.0991.
Compound 18 was prepared from 3-aminocyclohex-2-en-1-one (83
mg, 0.74 mmol), 3-methylbutanal (0.72 mL, 6.6 mmol), and N-(2,3-
dimethylphenyl)-3-oxobutanamide (144 mg, 0.70 mmol) according to
the general procedure THQ to give 22 mg (9%) of a white solid (tR =
11.08 min, purity 96.2% by HPLC) after purification by flash
chromatography (SiO2, EtOAc/petroleum ether, 1:1 → 1:0):
1H
NMR (400 MHz, CDCl3) δ 7.42 (s, 1H), 7.39 (d, J = 7.9 Hz, 1H), 7.09
(t, J = 7.7 Hz, 1H), 7.00 (d, J = 7.4 Hz, 1H), 6.32 (br s, 1H), 3.92 (t, J =
6.6 Hz, 1H), 2.53−2.45 (m, 1H), 2.42−2.37 (m, 2H), 2.34−2.30 (m,
1H), 2.30 (s, 3H), 2.26 (s, 3H), 2.18 (s, 3H), 2.04−1.90 (m, 2H),
1.64−1.51 (m, 1H), 1.27−1.24 (m, 2H), 0.97 (d, J = 6.5 Hz, 3H), 0.88
(d, J = 6.6Hz, 3H); 13CNMR (101MHz, CDCl3) δ 196.3, 167.5, 152.0,
139.8, 137.6, 135.7, 130.3, 127.4, 125.9, 122.7, 111.8, 109.8, 77.2, 47.0,
37.2, 29.7, 27.7, 24.1, 23.7, 23.0, 21.2, 20.7, 18.7, 14.3; ESI-HRMS calcd
for C23H30N2NaO2 (M + Na
+) 389.2199; found, 389.2202.
N-(2-Iodophenyl)-4-isobutyl-2-methyl-5-oxo-1,4,5,6,7,8-
hexahydroquinoline-3-carboxamide (19). A dry flask was charged
with 2-iodoaniline (258 mg, 1.18 mmol), 2,2,6-trimethyl-4H-1,3-
dioxin-4-one (0.22 mL, 1.20 mmol), and toluene (0.25 mL) and heated
to reflux under argon for 22 h. Afterward, the reaction was cooled to
room temperature and concentrated in vacuo. The residue was purified
by flash chromatography (SiO2, EtOAc/petroleum ether, 1:2) to give
113 mg (31%) of N-(2-iodophenyl)-3-oxobutanamide as a pale yellow
solid: Rf = 0.19 (SiO2, EtOAc/petroleum ether, 1:2);
1H NMR (400
MHz, CDCl3) δ 9.16 (br s, 1H), 8.12 (dd, J = 8.2, 1.0 Hz, 1H), 7.80 (dd,
J = 8.0, 1.4 Hz, 1H), 7.36−7.29 (m, 1H), 6.88−6.81 (m, 1H), 3.63 (s,
2H), 2.33 (s, 3H); 13C NMR (101MHz, CDCl3) δ 204.5, 163.8, 139.3,
138.5, 129.1, 126.5, 123.0, 90.2, 50.0, 31.4; ESI-HRMS calcd for
C10H10INNaO2 (M + Na
+) 325.9648; found, 325.9661.
Compound 19 was prepared from 3-aminocyclohex-2-en-1-one (40
mg, 0.36 mmol), 3-methylbutanal (39 μL, 0.36 mmol), and N-(2-
iodophenyl)-3-oxobutanamide (106 mg, 0.35 mmol) according to the
general procedure THQ to give 14 mg (9%) of a white solid (tR = 11.84
min, purity 98.4% byHPLC) after purification by flash chromatography
(SiO2, EtOAc/petroleum ether, 1:1):
1H NMR (400 MHz, CDCl3) δ
8.19 (dd, J = 8.2, 1.4 Hz, 1H), 7.82 (br s, 1H), 7.78 (dd, J = 7.9, 1.3 Hz,
1H), 7.36−7.30 (m, 1H), 6.82 (td, J = 7.6, 1.4 Hz, 1H), 6.12 (br s, 1H),
4.06 (dd, J = 7.9, 5.6 Hz, 1H), 2.53−2.42 (m, 3H), 2.36−2.26 (m, 1H),
2.30 (s, 3H), 2.11−1.93 (m, 2H), 1.60−1.50 (m, 1H), 1.35−1.23 (m,
2H), 0.99 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H); 13C NMR (101
MHz, CDCl3) δ 196.0, 167.0, 151.3, 140.6, 139.0, 138.9, 129.1, 125.8,
122.6, 112.2, 109.8, 90.8, 46.6, 37.2, 29.6, 27.8, 24.2, 23.8, 23.3, 21.2,
19.1; ESI-HRMS calcd for C21H25IN2NaO2 (M + Na
+) 487.0853;
found, 487.0875.
N-(2-Chlorophenyl)-4-isobutyl-2-methyl-5-oxo-1,4,5,6,7,8-
hexahydroquinoline-3-carboxamide (20). A dry flask was charged
with 2-chloroaniline (0.50 mL, 4.75 mmol), 2,2,6-trimethyl-4H-1,3-
dioxin-4-one (0.70 mL, 5.27 mmol), and toluene (1 mL) and heated to
reflux under argon for 6 h. Afterward, the reaction was cooled to room
temperature and concentrated in vacuo. The crude was dissolved in
boiling acetone, and petroleum ether was added until precipitation
started, and the solution was stored in the fridge overnight. The
precipitate was isolated by filtration, washed with petroleum ether, and
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dried to give 342 mg (34%) of N-(2-chlorophenyl)-3-oxobutanamide
as a beige solid, 90% pure by 1H NMR: Rf = 0.09 (SiO2, acetone/
petroleum ether, 1:4); 1H NMR (400 MHz, CDCl3) δ 9.61 (br s, 1H),
8.33 (dd, J = 8.3, 1.3 Hz, 1H), 7.38 (dd, J = 8.0, 1.4 Hz, 1H), 7.28−7.22
(m, 1H), 7.05 (dt, J = 7.9, 1.5 Hz, 1H), 3.64 (s, 2H), 2.34 (s, 3H); 13C
NMR (101 MHz, CDCl3) δ 204.9, 163.7, 134.7, 129.3, 127.7, 125.1,
123.6, 122.1, 49.8, 31.4.
Compound 20was prepared from 3-aminocyclohex-2-en-1-one (111
mg, 1.00 mmol), 3-methylbutanal (0.12 mL, 1.1 mmol), and N-(2-
chlorophenyl)-3-oxobutanamide (214 mg, 1.01 mmol) according to
the general procedure THQ to give 100 mg (27%) of a yellow foam (tR
= 11.55 min, purity 98.7% by HPLC) after purification by flash
chromatography (SiO2, EtOAc/petroleum ether, 1:1→ 1:0):
1H NMR
(400 MHz, CDCl3) δ 8.34 (dd, J = 8.3, 1.5 Hz, 1H), 7.99 (s, 1H), 7.36
(dd, J = 8.0, 1.5 Hz, 1H), 7.25 (dt, J = 8.2, 1.4 Hz, 1H), 7.04−6.98 (m,
1H), 6.36 (s, 1H), 3.96 (t, J = 6.8 Hz, 1H), 2.53−2.41 (m, 3H), 2.36−
2.25 (m, 4H), 2.09−1.90 (m, 2H), 1.59−1.47 (m, 1H), 1.30−1.25 (m,
2H), 0.98 (d, J = 6.4 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H); 13C NMR (101
MHz, CDCl3) δ 196.0, 166.8, 151.5, 141.0, 135.2, 129.2, 127.7, 124.4,
123.5, 122.1, 112.1, 109.6, 46.7, 37.2, 29.4, 27.8, 24.1, 23.7, 22.9, 21.2,
19.1; ESI-HRMS calcd for C21H26ClN2O2 (M + H
+) 373.1677; found,
373.1662.
N-(2,6-Difluorophenyl)-4-isobutyl-2-methyl-5-oxo-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (21). A dry flask
was charged with 2,6-difluoroaniline (0.18 mL, 1.67 mmol), 2,2,6-
trimethyl-4H-1,3-dioxin-4-one (0.22 mL, 1.66 mmol), and toluene (0.3
mL) and heated to reflux under argon for 22 h. Afterwards the reaction
was cooled to room temperature and concentrated in vacuo. The
residue was purified by flash chromatography (SiO2, EtOAc/petroleum
ether, 2:3) to give 182 mg (51%) of N-(2,6-difluorophenyl)-3-
oxobutanamide as a pale yellow solid: Rf = 0.19 (SiO2, EtOAc/
petroleum ether, 2:3); 1H NMR (400 MHz, CDCl3) δ 8.81 (br s, 1H),
7.18 (dq, J = 8.4, 6.2 Hz, 1H), 7.01−6.82 (m, 2H), 3.63 (s, 2H), 2.31 (s,
3H); 13CNMR (101MHz, CDCl3) δ 204.6, 164.5, 157.8 (dd, J = 250.9,
3.4 Hz), 127.9 (t, J = 9.1 Hz), 113.6 (t, J = 16.4 Hz), 111.8 (d, J = 22.1
Hz), 49.1, 30.9; ESI-HRMS calcd for C10H9F2NNaO2 (M + Na
+)
236.0494; found, 236.0465.
Compound 21 was prepared from 3-aminocyclohex-2-en-1-one (58
mg, 0.52 mmol), 3-methylbutanal (56 μL, 0.52 mmol), and N-(2,6-
difluorophenyl)-3-oxobutanamide (109 mg, 0.51 mmol) according to
the general procedure THQ to give 8 mg (4%) of a white solid (tR =
10.50 min, purity 99.9% by HPLC) after purification by flash
chromatography (SiO2, EtOAc/petroleum ether, 2:1):
1H NMR (400
MHz, CDCl3) δ 7.20 (br s, 1H), 7.19−7.12 (m, 1H), 6.98−6.91 (m,
2H), 6.06 (br s, 1H), 3.91 (t, J = 6.5 Hz, 1H), 2.53−2.40 (m, 3H),
2.35−2.23 (m, 1H), 2.28 (s, 3H), 2.10−1.92 (m, 2H), 1.67−1.54 (m,
1H), 1.31−1.21 (m, 2H), 0.95 (d, J = 6.5 Hz, 3H), 0.89 (d, J = 6.6 Hz,
3H); 13CNMR (101MHz, CDCl3) δ 196.3, 167.1, 158.0 (dd, J = 250.2,
4.3 Hz), 151.5, 141.1, 127.2 (t, J = 9.4Hz), 114.6 (t, J = 16.1 Hz), 112.4,
111.8 (d, J = 22.6 Hz), 108.6, 47.1, 37.2, 29.7, 27.8, 24.1, 23.5, 23.1,
21.2, 19.0; ESI-HRMS calcd for C21H24F2N2NaO2 (M + Na
+)
397.1698; found, 397.1703.
2-Ethyl-4-(furan-2-yl)-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahy-
droquinoline-3-carboxamide (22). A dry 5 mL vial under argon
atmosphere was charged with o-toluidine (0.21 mL, 1.98 mmol) and
methyl 3-oxopentanoate (0.25 mL, 1.99 mmol) and heated to 100 °C
for 17 h. The reaction was cooled to room temperature and purified by
flash column chromatography (SiO2, EtOAc/petroleum ether, 1:2) to
give 112 mg (28%) of 3-oxo-N-(o-tolyl)pentanamide as a yellow solid
that was used directly in the next step.
Compound 22was prepared from furan-2-carbaldehyde (55 μL, 0.66
mmol), 3-aminocyclohex-2-en-1-one (74 mg, 0.67 mmol), and 3-oxo-
N-(o-tolyl)pentanamide (132 mg, 0.64 mmol) according to the general
procedure THQ to give 56 mg (23%) of an orange foam (tR = 10.37
min, purity 95.7% byHPLC) after purification by flash chromatography
(SiO2, EtOAc/petroleum ether, 1:2 → 1:0):
1H NMR (400 MHz,
DMSO-d6) δ 9.04 (s, 1H), 8.80 (s, 1H), 7.43 (dd, J = 1.8, 0.9 Hz, 1H),
7.28−7.21 (m, 1H), 7.21−7.02 (m, 3H), 6.27 (dd, J = 3.1, 1.8 Hz, 1H),
5.93 (d, J = 3.1 Hz, 1H), 5.10 (s, 1H), 2.64−2.29 (m, 4H), 2.27−2.21
(m, 2H), 2.10 (s, 3H), 1.97−1.77 (m, 2H), 1.10 (t, J = 7.4 Hz, 3H); 13C
NMR (101MHz, DMSO-d6) δ 193.7, 166.9, 158.4, 153.1, 141.9, 141.0,
136.8, 132.5, 130.1, 125.7, 125.6, 125.0, 110.1, 106.8, 106.0, 104.5, 36.7,
31.9, 26.4, 23.7, 20.8, 17.8, 13.3; ESI-HRMS calcd for C23H24N2NaO3
(M + Na)+ 399.1679; found, 399.1685.
4-(Furan-2-yl)-5-oxo-2-phenyl-N-(o-tolyl)-1,4,5,6,7,8-hexa-
hydroquinoline-3-carboxamide (23). A dry 5 mL vial under argon
atmosphere was charged with o-toluidine (0.21 mL, 1.98 mmol) and
ethyl 3-oxo-3-phenylpropanoate (0.35 mL, 2.02 mmol) and heated to
100 °C for 17 h. The reaction was cooled to room temperature and
purified by flash column chromatography (SiO2, EtOAc/petroleum
ether, 1:4) to give 291 mg (58%) of 3-oxo-3-phenyl-N-(o-tolyl)-
propanamide as a pale yellow solid that was used directly in the next
step.
Compound 23was prepared from furan-2-carbaldehyde (55 μL, 0.66
mmol), 3-aminocyclohex-2-en-1-one (71 mg, 0.64 mmol), and 3-oxo-
3-phenyl-N-(o-tolyl)propanamide (160 mg, 0.63 mmol) according to
the general procedure THQ to give 155 mg (58%) of a beige solid (tR =
10.83 min, purity 96.9% by HPLC) after washing the crude with cold
EtOAc: 1H NMR (400 MHz, DMSO-d6) δ 9.06 (s, 1H), 8.33 (s, 1H),
7.47−7.41 (m, 6H), 7.23−7.15 (m, 1H), 7.08−7.00 (m, 2H), 6.99−
6.92 (m, 1H), 6.30 (dd, J = 3.1, 1.8 Hz, 1H), 6.03 (d, J = 3.2 Hz, 1H),
5.14 (s, 1H), 2.62−2.45 (m, 2H), 2.33−2.23 (m, 2H), 2.00−1.76 (m,
2H), 1.66 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ 194.0, 166.5,
158.2, 153.3, 141.0, 137.9, 136.3, 135.0, 131.0, 129.9, 129.1, 128.8,
128.3, 125.6, 124.6, 124.0, 110.2, 109.2, 106.1, 104.6, 36.8, 32.2, 26.4,
20.8, 16.9; ESI-HRMS calcd for C27H24N2NaO3 (M + Na)
+ 447.1679;
found, 447.1696.
4-(Furan-2-yl)-2-methyl-5-oxo-N-(o-tolyl)-5,6,7,8-tetrahy-
droquinoline-3-carboxamide (24). 4-(Furan-2-yl)-2-methyl-5-oxo-
N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (100 mg,
0.28 mmol) and MnO2 (400 mg, 4.60 mmol) were dissolved in
CHCl3 (13 mL) and stirred at room temperature for 19 h. The reaction
mixture was filtered through a pad of Celite and concentrated in vacuo
to give 59 mg (60%) of 24 as a yellow solid (tR = 9.88 min, purity 97.0%
by HPLC): 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 7.9 Hz, 1H),
7.51 (d, J = 1.1 Hz, 1H), 7.24−7.07 (m, 3H), 6.98 (br s, 1H), 6.58 (dd, J
= 3.4, 0.4 Hz, 1H), 6.47 (dd, J = 3.4, 1.8 Hz, 1H), 3.17 (t, J = 6.2 Hz,
2H), 2.73 (s, 3H), 2.71−2.65 (m, 2H), 2.25−2.15 (m, 2H), 2.04 (s,
3H); 13C NMR (101 MHz, CDCl3) δ 196.7, 165.6, 164.7, 159.5, 148.0,
143.6, 136.0, 134.9, 132.3, 130.7, 130.0, 126.9, 126.2, 124.5, 123.7,
111.9, 111.2, 39.8, 33.5, 23.4, 21.5, 17.7; ESI-HRMS calcd for
C22H21N2O3 (M + H)
+ 361.1547; found, 361.1562.
5-Benzoyl-4-isobutyl-2,6-dimethyl-N-(o-tolyl)-1,4-dihydro-
pyridine-3-carboxamide (25). Amicrowave vial was charged with 1-
phenylbutane-1,3-dione (163 mg, 1.01 mmol), IPA (2.5 mL), and
NH4OAc (83 mg, 1.08 mmol) and stirred at room temperature under
an argon atmosphere for two days. Afterward, 3-methylbutanal (0.12
mL, 1.11 mmol) and 3-oxo-N-(o-tolyl)butanamide (192 mg, 1.00
mmol) was added, and the microwave vial was capped and heated to 80
°C. After three days, the reaction was cooled to room temperature,
diluted with EtOAc, and concentrated in vacuo on Celite. The residue
was purified by flash column chromatography (SiO2, EtOAc/petroleum
ether, 1:1) to give 128 mg (32%) of 25 as a bright yellow foam (tR =
12.54 min, 95.1% pure by HPLC): 1H NMR (400 MHz, CDCl3) δ
7.86−7.81 (m, 1H), 7.73−7.66 (m, 2H), 7.51−7.45 (m, 1H), 7.45−
7.39 (m, 2H), 7.24−7.11 (m, 3H), 7.08−7.02 (m, 1H), 6.08 (br s, 1H),
3.77−3.69 (m, 1H), 2.37 (s, 3H), 2.15 (s, 3H), 2.02 (s, 3H), 1.67−1.55
(m, 1H), 1.44−1.35 (m, 1H), 1.15−1.08 (m, 1H), 0.78 (d, J = 6.6 Hz,
3H), 0.67 (d, J = 6.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 198.3,
166.8, 142.4, 141.9, 140.4, 136.3, 131.7, 130.6, 129.2, 128.7, 128.6,
126.8, 124.9, 123.4, 112.5, 106.7, 46.9, 35.5, 23.7, 23.6, 22.3, 19.2, 18.9,
18.1; ESI-HRMS calcd for C26H30N2NaO2 (M + Na)
+ 425.2199;
found, 425.2218.
Methyl 4-isobutyl-2,6-dimethyl-5-(o-tolylcarbamoyl)-1,4-di-
hydropyridine-3-carboxylate (26). Compound 26 was prepared
from methyl (E)-3-aminobut-2-enoate (112 mg, 0.97 mmol), 3-
methylbutanal (0.15 mL, 1.39 mmol), and 3-oxo-N-(o-tolyl)-
butanamide (192 mg, 1.00 mmol) according to the general procedure
THQ to give 207 mg (60%) of a pale yellow foam (tR = 12.03 min,
98.6% pure by HPLC) after purification by flash chromatography
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(SiO2, EtOAc/petroleum ether, 1:1):
1HNMR (400MHz, acetone-d6)
δ 8.21 (br s, 1H), 7.70−7.64 (m, 1H), 7.59 (br s, 1H), 7.22−7.12 (m,
2H), 7.06−7.00 (m, 1H), 3.89 (t, J = 6.7 Hz, 1H), 3.64 (s, 3H), 2.30 (s,
3H), 2.29 (s, 3H), 2.20 (s, 3H), 1.77−1.64 (m, 1H), 1.37−1.26 (m,
1H), 1.25−1.15 (m, 1H), 0.89 (dd, J = 6.5, 3.2 Hz, 6H); 13CNMR (101
MHz, acetone-d6) δ 168.8, 168.7, 147.5, 138.4, 138.3, 131.7, 131.1,
126.9, 125.4, 125.0, 110.1, 101.5, 50.7, 47.9, 34.1, 24.6, 23.7, 23.5, 19.1,
18.5, 17.7; ESI-HRMS calcd for C21H28N2NaO3 (M + Na)
+ 379.1992;
found, 379.1992.
5-Cyano-4-isobutyl-2,6-dimethyl-N-(o-tolyl)-1,4-dihydro-
pyridine-3-carboxamide (27). Compound 27 was prepared from
(E)-3-aminobut-2-enenitrile (84 mg, 1.02 mmol), 3-methylbutanal
(0.15 mL, 1.39 mmol), and 3-oxo-N-(o-tolyl)butanamide (192 mg,
1.01 mmol) according to the general procedure THQ to give 209 mg
(64%) of a white solid (tR = 11.55 min, 97.6% pure by HPLC) after
purification by flash chromatography (SiO2, EtOAc/petroleum ether,
1:1): 1H NMR (400 MHz, acetone-d6) δ 8.49 (br s, 1H), 7.79 (br s,
1H), 7.56−7.50 (m, 1H), 7.24−7.12 (m, 2H), 7.11−7.04 (m, 1H),
3.61−3.53 (m, 1H), 2.29 (s, 3H), 2.15 (s, 3H), 2.07 (s, 3H), 2.02−1.89
(m, 1H), 1.49−1.32 (m, 2H), 0.93 (dd, J = 15.5, 6.6 Hz, 6H); 13CNMR
(101 MHz, acetone-d6) δ 168.3, 148.7, 137.9, 137.4, 132.7, 131.2,
126.9, 125.9, 125.8, 121.4, 108.7, 82.8, 48.3, 35.6, 24.7, 23.9, 22.8, 18.6,
18.1, 17.8; ESI-HRMS calcd for C20H26N3O (M + H)
+ 324.2070;
found, 324.2086.
Methyl 4-isobutyl-2-methyl-5-oxo-1,4,5,6,7,8-hexahydro-
quinoline-3-carboxylate (28). Compound 28 was prepared from
3-aminocyclohex-2-en-1-one (112 mg, 1.01 mmol), 3-methylbutanal
(0.15 mL, 1.39 mmol), and methyl 3-oxobutanoate (0.15 mL, 1.39
mmol) according to the general procedure THQ to give 178 mg (64%)
of a pale yellow solid (tR = 10.77 min, 96.0% pure by HPLC) after
purification by flash chromatography (SiO2, EtOAc/petroleum ether,
1:1→ 1:0): 1HNMR (400MHz, DMSO-d6) δ 9.02 (s, 1H), 3.83 (t, J =
6.7 Hz, 1H), 3.59 (s, 3H), 2.45−2.33 (m, 2H), 2.20 (s, 3H), 2.29−2.10
(m, 2H), 1.94−1.70 (m, 2H), 1.39−1.27 (m, 1H), 1.00−0.88 (m, 2H),
0.82 (d, J = 6.5 Hz, 3H), 0.78 (d, J = 6.6 Hz, 3H); 13C NMR (101MHz,
DMSO-d6) δ 194.9, 167.7, 151.9, 145.2, 111.2, 103.7, 50.5, 46.9, 36.8,
27.0, 26.2, 23.4, 23.2, 23.0, 20.9, 18.1; ESI-HRMS calcd for
C16H23NNaO3 (M + Na)
+ 300.1570; found, 300.1570.
3-Benzoyl-4-isobutyl-2-methyl-4,6,7,8-tetrahydroquinolin-
5(1H)-one (29). Compound 29 was prepared from 3-aminocyclohex-
2-en-1-one (112 mg, 1.01 mmol), 3-methylbutanal (0.1 mL, 0.91
mmol), and 1-phenylbutane-1,3-dione (163 mg, 1.01 mmol) according
to the general procedure THQ to give 100 mg (34%) of a yellow solid
(tR = 11.38 min, purity 98.2% by HPLC) after purification by flash
chromatography (SiO2, EtOAc/petroleum ether, 1:1):
1H NMR (400
MHz, CDCl3) δ 7.70−7.64 (m, 2H), 7.50−7.43 (m, 1H), 7.42−7.35
(m, 2H), 6.88 (br s, 1H), 4.00 (dd, J = 7.7, 5.9 Hz, 1H), 2.52−2.39 (m,
3H), 2.39−2.28 (m, 1H), 2.08−1.89 (m, 2H), 1.97 (s, 3H), 1.52−1.37
(m, 1H), 1.22−1.12 (m, 1H), 1.02−0.91 (m, 1H), 0.73 (d, J = 6.5 Hz,
3H), 0.62 (d, J = 6.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 199.0,
196.2, 151.8, 139.4, 139.1, 132.0, 128.9, 128.6, 116.4, 112.5, 47.4, 37.4,
30.7, 27.7, 24.1, 23.4, 22.5, 21.4, 18.3; ESI-HRMS calcd for C21H26NO2
(M + H+) 324.1958; found, 324.1972.
4-(sec-Butyl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahy-
droquinoline-3-carboxamide (30). Compound 30 was prepared
from 3-aminocyclohex-2-en-1-one (112 mg, 1.01 mmol), 2-methyl-
butanal (108 μL, 1.01 mmol), and 3-oxo-N-(o-tolyl)butanamide (193
mg, 1.01mmol) according to the general procedure THQ to give 18mg
(5%) of a white solid and mixture of diasteromers (tR = 10.6 min, 97.6%
pure by HPLC) after purification by flash chromatography (SiO2,
EtOAc/petroleum ether, 4:1) followed by washing with petroleum
ether: 1H NMR (400 MHz, acetone-d6) δ 8.40 (br s, 1H), 8.39 (br s,
1H), 7.75 (br s, 1H), 7.69 (br s, 1H), 7.66−7.58 (m, 2H), 7.20 (d, J =
7.5 Hz, 2H), 7.15 (t, J = 7.6 Hz, 2H), 7.04 (t, J = 7.5 Hz, 2H), 4.02 (d, J
= 3.4 Hz, 1H), 3.99 (d, J = 3.2 Hz, 1H), 2.54−2.45 (m, 4H), 2.37−2.27
(m, 2H), 2.30 (s, 6H), 2.25−2.15 (m, 2H), 2.19 (d, J = 6.0 Hz, 6H),
2.02−1.87 (m, 4H), 1.57−1.37 (m, 4H), 1.19−1.01 (m, 2H), 0.85 (t, J
= 7.3 Hz, 6H), 0.82 (d, J = 1.8 Hz, 3H), 0.80 (d, J = 1.8 Hz, 3H); ESI-
HRMS calcd for C22H29N2O2 (M + H)
+ 353.2224; found, 353.2239.
4-Cyclohexyl-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexa-
hydroquinoline-3-carboxamide (31). Compound 31 was prepared
from 3-aminocyclohex-2-en-1-one (111 mg, 1.00 mmol), cyclo-
hexanecarboxaldehyde (121 μL, 1.00 mmol), and 3-oxo-N-(o-tolyl)-
butanamide (191 mg, 1.00 mmol) according to the general procedure
THQ to give 16 mg (4%) of a brownish solid (tR = 11.18 min, purity
95.7% by HPLC) after purification by flash chromatography (SiO2,
EtOAc/petroleum ether, 1:3) followed by trituation with petroleum
ether in EtOAc: 1H NMR (CDCl3) δ 7.77 (d, J = 7.9 Hz, 1H), 7.34 (s,
1H), 7.22−7.15 (m, 2H), 7.05 (td, J = 7.5, 0.9 Hz, 1H), 5.96 (s, 1H),
3.81 (d, J = 4.9 Hz, 1H), 2.56−2.49 (m, 1H), 2.46−2.42 (m, 2H),
2.36−2.31 (m, 1H), 2.30 (s, 3H), 2.28 (s, 3H), 2.07−1.95 (m, 2H),
1.74−1.53 (m, 6H), 1.13−0.94 (m, 5H); 13C NMR (CDCl3) δ 196.4,
167.9, 152.1, 139.9, 136.2, 130.6, 129.6, 126.8, 125.0, 123.4, 109.8,
108.0, 46.1, 37.5, 37.3, 29.5, 29.1, 27.8, 26.7, 26.6, 21.2, 18.7, 18.2; ESI-
HRMS calcd for C24H31N2O2 (M + H)
+ 379.2380; found, 379.2393.
4-Cyclopentyl-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexa-
hydroquinoline-3-carboxamide (32). Compound 32 was prepared
from cyclopentanecarbaldehyde (110 μL, 1.03 mmol), 3-amino-
cyclohex-2-en-1-one (111 mg, 1.00 mmol), and 3-oxo-N-(o-tolyl)-
butanamide (192 mg, 1.00 mmol) according to the general procedure
THQ to give 16 mg (4%) of a white solid (tR = 10.78 min, purity 98.3%
by HPLC) after purification by flash chromatography (SiO2, EtOAc/
petroleum ether, 1:1→ 0:1): 1H NMR (500 MHz, DMSO-d6) δ 9.06
(s, 1H), 8.59 (s, 1H), 7.24 (d, J = 6.8 Hz, 1H), 7.20 (d, J = 7.4 Hz, 1H),
7.17−7.13 (m, 1H), 7.08 (td, J = 7.4, 1.1 Hz, 1H), 3.89 (d, J = 6.0 Hz,
1H), 2.47−2.33 (m, 2H), 2.29−2.12 (m, 2H), 2.20 (s, 3H), 2.09 (s,
3H), 1.95−1.70 (m, 2H), 1.59−1.40 (m, 4H), 1.40−1.28 (m, 2H),
1.27−1.15 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 194.6, 168.8,
153.2, 137.0, 135.2, 132.9, 130.2, 125.8 (two CH), 125.1, 110.0, 108.2,
48.0, 37.1, 34.2, 28.0, 27.9, 26.6, 24.3, 24.2, 20.9, 18.2, 17.1; ESI-HRMS
calcd for C23H29N2O2 (M + H)
+ 365.2224; found, 365.2234.
4-Cyclopropyl-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexa-
hydroquinoline-3-carboxamide (33). Compound 33 was prepared
from 3-aminocyclohex-2-en-1-one (116 mg, 1.05 mmol), cyclo-
propanecarboxaldehyde (78 μL, 1.05 mmol), and 3-oxo-N-(o-tolyl)-
butanamide (200 mg, 1.05 mmol) according to the general procedure
THQ to give 44 mg (13%) of a white solid (tR = 9.74 min, purity 98.3%
by HPLC) after purification by flash chromatography (SiO2, EtOAc/
petroleum ether, 1:5): 1H NMR (CDCl3) δ 7.73 (d, J = 7.9 Hz, 1H),
7.48 (s, 1H), 7.23−7.16 (m, 2H), 7.10−7.04 (m, 1H), 5.92 (s, 1H),
3.79 (d, J = 6.7 Hz, 1H), 2.55−2.47 (m, 1H), 2.45−2.40 (m, 2H),
2.38−2.32 (m, 1H), 2.30 (s, 3H), 2.29 (s, 3H), 2.08−1.99 (m, 2H),
1.09−0.96 (m, 1H), 0.47−0.31 (m, 3H), 0.30−0.18 (m, 1H); 13C
NMR (CDCl3) δ 196.3, 167.2, 151.1, 140.8, 136.2, 130.7, 129.9, 126.8,
125.1, 123.7, 111.3, 107.1, 37.2, 32.8, 27.7, 21.4, 19.0, 18.3, 2.9, 2.8;
ESI-HRMS calcd for C21H24N2NaO2 (M + Na)
+ 359.1730; found,
359.1717.
4-Ethyl-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahydro-
quinoline-3-carboxamide (34). Compound 34 was prepared from
3-aminocyclohex-2-en-1-one (111 mg, 1.00 mmol), propionaldehyde
(0.08 mL, 1.10 mmol), and 3-oxo-N-(o-tolyl)butanamide (193 mg,
1.01 mmol) according to the general procedure THQ to give 46 mg
(14%) of a pale yellow foam (tR = 9.65 min, 96.6% pure by HPLC) after
purification by flash chromatography (SiO2, EtOAc/petroleum ether,
1:1): 1H NMR (400 MHz, CDCl3) δ 7.73−7.68 (m, 1H), 7.38 (br s,
1H), 7.21−7.15 (m, 2H), 7.09−7.03 (m, 1H), 6.24 (br s, 1H), 3.92 (t, J
= 5.1 Hz, 1H), 2.51−2.29 (m, 4H), 2.27 (s, 3H), 2.26 (s, 2H), 2.03−
1.91 (m, 2H), 1.62−1.50 (m, 1H), 1.50−1.38 (m, 1H), 0.82 (t, J = 7.5
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 196.1, 167.2, 152.3, 140.1,
136.1, 130.6, 130.1, 126.8, 125.2, 123.8, 110.3, 108.4, 37.2, 33.0, 29.0,
27.6, 21.4, 18.7, 18.1, 9.4; ESI-HRMS calcd for C20H25N2O2 (M + H)
+
325.1911; found, 325.1925.
2-Methyl-5-oxo-4-propyl-N-(o-tolyl)-1,4,5,6,7,8-hexahydro-
quinoline-3-carboxamide (35). Compound 35 was prepared from
3-aminocyclohex-2-en-1-one (113 mg, 1.01 mmol), butyraldehyde (91
μL, 1.01 mmol), and 3-oxo-N-(o-tolyl)butanamide (193 mg, 1.01
mmol) according to the general procedure THQ to give 92 mg (27%)
of a pale yellow solid (tR = 10.25 min, 98.4% pure by HPLC) after
purification by flash chromatography (SiO2, EtOAc) followed by
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washing with petroleum ether: 1H NMR (400MHz, acetone-d6) δ 8.36
(br s, 1H), 7.71 (br s, 1H), 7.66−7.58 (m, 1H), 7.23−7.11 (m, 2H),
7.08−7.02 (m, 1H), 3.96 (t, J = 4.5 Hz, 1H), 2.49−2.44 (m, 2H), 2.30
(s, 3H), 2.34−2.16 (m, 4H), 2.19 (s, 3H), 2.01−1.83 (m, 2H), 1.54−
1.41 (m, 1H), 1.41−1.23 (m, 3H), 0.87−0.80 (m, 3H); 13C NMR (101
MHz, acetone-d6) δ 195.1, 168.4, 153.3, 153.2, 138.2, 138.1, 132.4,
131.1, 126.8, 125.59, 125.55, 125.4, 110.9, 110.9, 110.84, 110.81, 110.6,
110.5, 39.8, 38.0, 32.8, 27.7, 27.6, 22.2, 18.9, 18.5, 17.82, 17.75, 14.8
(contains rotamers); ESI-HRMS calcd for C21H27N2O2 (M + H)
+
339.2067; found, 339.2077.
2-Methyl-5-oxo-4-butyl-N-(o-tolyl)-1,4,5,6,7,8-hexahydro-
quinoline-3-carboxamide (36). Compound 36 was prepared from
3-aminocyclohex-2-en-1-one (111 mg, 1.00 mmol), pentanal (0.15 mL,
1.41 mmol), and 3-oxo-N-(o-tolyl)butanamide (191 mg, 1.00 mmol)
according to the general procedure THQ to give 145 mg (41%) of a
yellow solid (tR = 10.75min, 96.5% pure byHPLC) after purification by
flash chromatography (SiO2, EtOAc) followed by washing with
petroleum ether: 1H NMR (400 MHz, CDCl3) δ 7.72−7.66 (m,
1H), 7.39 (s, 1H), 7.21−7.15 (m, 2H), 7.09−7.03 (m, 1H), 6.44 (s,
1H), 3.91 (t, J = 5.4 Hz, 1H), 2.46 (dt, J = 16.7, 4.6 Hz, 1H), 2.41−2.28
(m, 3H), 2.27 (s, 3H), 2.25 (s, 3H), 2.04−1.90 (m, 2H), 1.56−1.45 (m,
1H), 1.45−1.31 (m, 1H), 1.31−1.17 (m, 4H), 0.84 (t, J = 6.8 Hz, 3H);
13C NMR (101 MHz, CDCl3) δ 196.1, 167.2, 152.2, 140.1, 136.1,
130.6, 130.1, 126.7, 125.3, 123.9, 110.9, 108.8, 37.2, 36.5, 32.0, 27.5,
27.3, 23.1, 21.3, 18.7, 18.2, 14.3; ESI-HRMS calcd for C22H29N2O2 (M
+ H)+ 353.2224; found, 353.2206.
2-Methyl-5-oxo-4-pentyl-N-(o-tolyl)-1,4,5,6,7,8-hexahydro-
quinoline-3-carboxamide (37). Compound 37 was prepared from
3-aminocyclohex-2-en-1-one (111 mg, 1.00 mmol), hexanal (0.12 mL,
0.99 mmol), and 3-oxo-N-(o-tolyl)butanamide (193 mg, 1.01 mmol)
according to the general procedure THQ to give 105 mg (29%) of a
yellow solid (tR = 11.36min, 96.5% pure byHPLC) after purification by
flash chromatography (SiO2, EtOAc/petroleum ether, 2:3) followed by
washing with petroleum ether: 1H NMR (400MHz, acetone-d6) δ 8.40
(br s, 1H), 7.74 (br s, 1H), 7.62−7.56 (m, 1H), 7.22−7.18 (m, 1H),
7.18−7.12 (m, 1H), 7.08−7.02 (m, 1H), 4.00−3.93 (m, 1H), 2.49−
2.43 (m, 2H), 2.30 (s, 3H), 2.35−2.20 (m, 2H), 2.18 (s, 3H), 2.03−
1.83 (m, 2H), 1.40−1.17 (m, 8H), 0.84 (t, J = 6.9 Hz, 3H); 13C NMR
(101 MHz, acetone-d6) δ 195.2, 168.5, 153.3, 153.2, 138.2, 138.1,
132.5, 132.3, 131.1, 126.8, 125.62, 125.60, 125.5, 110.9, 110.6, 38.0,
37.2, 33.1, 32.9, 27.7, 27.6, 25.4, 23.4, 22.2, 18.5, 17.82, 17.75, 14.4
(contains rotamers); ESI-HRMS calcd for C23H31N2O2 (M + H)
+
367.2380; found, 367.2363.
2-Methyl-5-oxo-4-phenethyl-N-(o-tolyl)-1,4,5,6,7,8-hexahy-
droquinoline-3-carboxamide (38). Compound 38 was prepared
from 3-aminocyclohex-2-en-1-one (111 mg, 1.00 mmol), 3-phenyl-
propanal (0.15 mL, 1.14 mmol), and 3-oxo-N-(o-tolyl)butanamide
(191 mg, 1.00 mmol) according to the general procedure THQ to give
123 mg (31%) of a pale yellow solid (tR = 11.08 min, 97.1% pure by
HPLC) after purification by flash chromatography (SiO2, EtOAc/
petroleum ether, 1:2 → 1:1); 1H NMR (400 MHz, CDCl3) δ 7.70−
7.63 (m, 1H), 7.33 (br s, 1H), 7.24−7.03 (m, 9H), 6.41 (br s, 1H), 4.04
(t, J = 5.2 Hz, 1H), 2.65−2.56 (m, 2H), 2.48−2.28 (m, 4H), 2.26 (s,
3H), 2.22 (s, 3H), 2.02−1.83 (m, 3H), 1.81−1.68 (m, 1H); 13C NMR
(101 MHz, CDCl3) δ 196.1, 167.1, 152.4, 142.6, 139.9, 136.0, 130.6,
130.3, 128.4, 128.3, 126.7, 125.7, 125.4, 124.0, 110.6, 108.7, 38.0, 37.2,
32.0, 31.5, 27.6, 21.3, 18.7, 18.1; ESI-HRMS calcd for C26H29N2O2 (M
+ H)+ 401.2224; found, 401.2206.
4-(2-(1H-Pyrazol-1-yl)ethyl)-N-(2,5-dichlorophenyl)-2-meth-
yl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (40).
Compound 40 was prepared from 3-(1H-pyrazol-1-yl)propanal (62
mg, 0.5 mmol), 3-aminocyclohex-2-en-1-one (56 mg, 0.5 mmol), and
N-(2,5-dichlorophenyl)-3-butanamide (123 mg, 0.5 mmol) according
to the general procedure THQ to give 8 mg (4%) of a pale gray solid (tR
= 10.75 min, purity 98.2% by HPLC) after purification by flash
chromatography (Reveleris X2, 12 g, MeOH in DCM, 0% to 10%): 1H
NMR (400 MHz, CDCl3) δ 8.36 (d, J = 4.9 Hz, 1H), 8.17 (s, 1H),
7.45−7.40 (m, 1H), 7.29 (d, J = 8.6 Hz, 1H), 7.21 (s, 1H), 702 (dd, J =
8.6, 2.5 Hz, 1H), 6.19 (t, J = 2.1 Hz, 1H), 4.19−4.03 (m, 3H), 2.51−
2.39 (m, 3H), 2.37−2.13 (m, 5H), 2.07−1.81 (m, 3H); 13C NMR (101
MHz, CDCl3) δ 196.0, 166.3, 152.6, 141.5, 138.9, 135.8, 133.3, 129.7,
129.5, 124.6, 122.4, 122.0, 110.0, 107.5, 105.3, 48.7, 37.0, 36.5, 29.5,
27.4, 21.1, 18.8; ESI-HRMS calcd for C22H22Cl2N4NaO2 (M + Na)
+
467.1012; found, 467.1005.
2-Methyl-4-(1-methyl-1H-pyrrol-2-yl)-5-oxo-N-(o-tolyl)-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (41). Com-
pound 41 was prepared from 1-methyl-1H-pyrrole-2-carbaldehyde
(55 μL, 0.51 mmol), 3-aminocyclohex-2-en-1-one (57 mg, 0.51 mmol),
and 3-oxo-N-(o-tolyl)butanamide (90mg, 0.51mmol) according to the
general procedure THQ to give 8 mg (4%) of a yellow foam (tR = 10.17
min, purity 82.1% byHPLC) after purification by flash chromatography
(SiO2, EtOAc/petroleum ether, 2:1):
1H NMR (400 MHz, DMSO-d6)
δ 8.84 (s, 1H), 8.72 (s, 1H), 7.20−7.01 (m, 4H), 6.42−6.37 (m, 1H),
5.80−5.77 (m, 1H), 5.70 (dd, J = 3.5, 1.9 Hz, 1H), 4.89 (s, 1H), 3.61 (s,
3H), 2.48−2.43 (m, 2H), 2.21−2.15 (m, 2H), 2.08 (s, 3H), 1.93−1.70
(m, 2H), 1.89 (s, 3H); 13CNMR (101MHz, DMSO-d6) δ 194.1, 167.4,
151.4, 138.7, 136.6, 133.3, 132.5, 130.1, 125.7, 125.4, 125.0, 120.4,
110.4, 109.0, 106.9, 106.1, 36.8, 33.5, 29.7, 26.4, 20.8, 17.6, 17.0; ESI-
HRMS calcd for C23H25N3NaO2 (M + Na)
+ 398.1839; found,
398.1856.
2-Methyl-4-(5-methylfuran-2-yl)-5-oxo-N-(o-tolyl)-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (42). Com-
pound 42 was prepared from 5-methylfuran-2-carbaldehyde (50 μL,
0.50 mmol), 3-aminocyclohex-2-en-1-one (57 mg, 0.51 mmol), and 3-
oxo-N-(o-tolyl)butanamide (89 mg, 0.50 mmol) according to the
general procedure THQ to give 69mg (37%) of a pale yellow foam (tR =
10.28 min, purity 99.9% by HPLC) after purification by flash
chromatography (SiO2, EtOAc/petroleum ether, 2:1):
1H NMR (400
MHz, DMSO-d6) δ 9.03 (s, 1H), 8.81 (s, 1H), 7.27−7.23 (m, 1H),
7.21−7.11 (m, 2H), 7.10−7.04 (m, 1H), 5.88−5.83 (m, 1H), 5.73 (d, J
= 3.0 Hz, 1H), 5.02 (s, 1H), 2.54−2.43 (m, 2H), 2.29−2.20 (m, 2H),
2.16 (d, J = 0.7 Hz, 3H), 2.15 (s, 3H), 2.09 (s, 3H), 1.98−1.81 (m, 2H);
13C NMR (101 MHz, DMSO-d6) δ 193.8, 167.1, 156.8, 152.9, 149.3,
136.9, 135.9, 132.7, 130.1, 125.7, 125.6, 125.0, 107.8, 106.1, 105.9,
105.0, 36.8, 31.5, 26.4, 20.9, 17.9, 17.2, 13.4; ESI-HRMS calcd for
C23H24N2NaO3 (M + Na)
+ 399.1679; found, 399.1696.
2-Methyl-4-(4-methylthiophen-2-yl)-5-oxo-N-(o-tolyl)-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (43). Com-
pound 43 was prepared from 4-methylthiophene-2-carbaldehyde (65
μL, 0.53 mmol), 3-aminocyclohex-2-en-1-one (56mg, 0.50 mmol), and
3-oxo-N-(o-tolyl)butanamide (89 mg, 0.50 mmol) according to the
general procedure THQ to give 66 mg (34%) of a pale orange foam (tR
= 10.89 min, purity 98.6% by HPLC) after purification by flash
chromatography (SiO2, EtOAc/petroleum ether, 2:1):
1H NMR (400
MHz, DMSO-d6) δ 8.93 (s, 1H), 8.90 (s, 1H), 7.32−7.25 (m, 1H), 7.14
(dt, J = 9.1, 4.6 Hz, 2H), 7.05 (td, J = 7.4, 1.3 Hz, 1H), 6.80−6.76 (m,
1H), 6.60 (s, 1H), 5.19 (s, 1H), 2.52−2.44 (m, 2H), 2.28−2.21 (m,
2H), 2.15 (s, 3H), 2.10 (d, J = 0.9 Hz, 3H), 2.02 (s, 3H), 1.96−1.75 (m,
2H); 13C NMR (101 MHz, DMSO-d6) δ 193.9, 166.9, 152.0, 151.1,
136.7, 136.2, 136.1, 132.3, 130.1, 125.7, 125.4, 125.3, 125.0, 118.8,
109.4, 108.9, 36.7, 32.7, 26.3, 20.8, 17.7, 17.3, 15.5; ESI-HRMS calcd
for C23H24N2NaO2S (M + Na)
+ 415.1451; found, 415.1457.
4-(5-Bromofuran-2-yl)-2-methyl-5-oxo-N-(o-tolyl)-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (44). Com-
pound 44 was prepared from 5-bromofuran-2-carbaldehyde (88 mg,
0.50 mmol), 3-aminocyclohex-2-en-1-one (56 mg, 0.50 mmol), and 3-
oxo-N-(o-tolyl)butanamide (89 mg, 0.50 mmol) according to the
general procedure THQ to give 84mg (38%) of a pale yellow solid (tR =
10.59 min, purity 99.9% by HPLC) after purification by flash
chromatography (SiO2, EtOAc/petroleum ether, 2:1):
1H NMR (400
MHz, DMSO-d6) δ 9.18 (s, 1H), 8.88 (s, 1H), 7.27−7.04 (m, 4H), 6.35
(d, J = 3.2 Hz, 1H), 5.94 (dd, J = 3.3, 0.7 Hz, 1H), 5.09 (s, 1H), 2.55−
2.42 (m, 2H), 2.30−2.19 (m, 2H), 2.14 (s, 3H), 2.09 (s, 3H), 1.98−
1.81 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 193.8, 166.9, 160.8,
153.4, 136.7, 135.7, 133.1, 130.1, 126.0, 125.7, 125.3, 118.3, 112.0,
107.4, 107.3, 105.0, 36.7, 32.1, 26.4, 20.8, 18.0, 17.2; ESI-HRMS calcd
for C22H21BrN2NaO3 (M + Na)
+ 463.0628; found, 463.0617.
4-(Benzofuran-2-yl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-
hexahydroquinoline-3-carboxamide (45). Compound 45 was
prepared from benzofuran-2-carbaldehyde (65 μL, 0.54 mmol), 3-
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aminocyclohex-2-en-1-one (57 mg, 0.51 mmol), and 3-oxo-N-(o-
tolyl)butanamide (89 mg, 0.50 mmol) according to the general
procedure THQ to give 67 mg (32%) of a pale yellow foam (tR = 10.89
min, purity 96.1% byHPLC) after purification by flash chromatography
(SiO2, EtOAc/petroleum ether, 2:1):
1H NMR (400 MHz, DMSO-d6)
δ 9.22 (s, 1H), 8.93 (s, 1H), 7.52−7.38 (m, 2H), 7.27−7.04 (m, 6H),
6.38 (s, 1H), 5.26 (s, 1H), 2.57−2.48 (m, 2H), 2.32−2.25 (m, 2H),
2.12 (s, 3H), 2.11 (s, 3H), 1.98−1.88 (m, 2H); 13C NMR (101 MHz,
DMSO-d6) δ 193.9, 167.0, 161.6, 154.0, 153.6, 136.7, 135.9, 133.0,
130.1, 128.5, 125.9, 125.7, 125.2, 123.1, 122.4, 120.4, 110.7, 107.4,
105.1, 101.2, 36.7, 32.4, 26.5, 20.9, 17.9, 17.2; ESI-HRMS calcd for
C26H24N2NaO3 (M + Na)
+ 435.1679; found, 435.1686.
4-(Benzo[b]thiophen-3-yl)-2-methyl-5-oxo-N-(o-tolyl)-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (46). Com-
pound 46 was prepared from benzo[b]thiophene-3-carbaldehyde (83
mg, 0.51 mmol), 3-aminocyclohex-2-en-1-one (56 mg, 0.50 mmol) and
3-oxo-N-(o-tolyl)butanamide (89 mg, 0.50 mmol) according to the
general procedure THQ to give 60mg (28%) of a pale yellow foam (tR =
11.10 min, purity 94.3% by HPLC) after purification by flash
chromatography (SiO2, EtOAc/petroleum ether, 2:1):
1H NMR (400
MHz, DMSO-d6) δ 8.96 (s, 1H), 8.91 (s, 1H), 8.09−8.03 (m, 1H),
7.91−7.85 (m, 1H), 7.35−7.27 (m, 2H), 7.24 (s, 1H), 7.11−6.98 (m,
5H), 5.39 (s, 1H), 2.59−2.46 (m, 2H), 2.27−2.15 (m, 2H), 2.11 (s,
3H), 1.97−1.79 (m, 2H), 1.77 (s, 3H); 13C NMR (101 MHz, DMSO-
d6) δ 193.9, 167.3, 152.7, 142.4, 139.9, 137.8, 136.5, 133.9, 132.6, 130.0,
125.60, 125.58, 125.1, 123.7, 123.6, 123.5, 123.0, 122.5, 110.5, 108.2,
36.8, 32.1, 26.5, 20.8, 17.5, 17.0; ESI-HRMS calcd for C26H24N2NaO2S
(M + Na)+ 451.1451; found, 451.1429.
N-(2,5-Dichlorophenyl)-2-methyl-5-oxo-4-(thiazol-2-yl)-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (47). Com-
pound 47 was prepared from thiazole-2-carbaldehyde (50 μL, 0.57
mmol), 3-aminocyclohex-2-en-1-one (56 mg, 0.50 mmol), andN-(2,5-
dichlorophenyl)-3-oxobutanamide (123 mg, 0.50 mmol) according to
the general procedure THQ to give 95 mg (44%) of a pale yellow solid
(tR = 11.68 min, purity 98.2% by HPLC) after purification by filtration
followed by washing with IPA: 1HNMR (500MHz, DMSO-d6) δ 10.76
(s, 1H), 9.52 (s, 1H), 8.11 (d, J = 2.6 Hz, 1H), 7.76 (d, J = 3.3 Hz, 1H),
7.56 (d, J = 3.3 Hz, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.21 (dd, J = 8.6, 2.6
Hz, 1H), 5.23 (s, 1H), 2.61 (dd, J = 7.5, 4.7 Hz, 2H), 2.34 (dd, J = 8.0,
5.0 Hz, 2H), 2.13 (s, 3H), 2.08−1.88 (m, 2H); 13C NMR (101 MHz,
DMSO-d6) δ 194.2, 177.4, 166.2, 154.0, 143.2, 142.4, 137.2, 131.5,
130.7, 124.6, 123.4, 123.0, 119.9, 107.4, 105.7, 36.6, 34.1, 26.2, 20.8,
17.9; ESI-HRMS calcd for C20H18Cl2N3O2S (M + H)
+ 434.0491;
found, 434.0510.
N-(2,5-Dichlorophenyl)-2-methyl-5-oxo-4-(thiazol-5-yl)-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (48). Com-
pound 48 was prepared from thiazole-5-carbaldehyde (50 μL, 0.58
mmol), 3-aminocyclohex-2-en-1-one (56 mg, 0.50 mmol), andN-(2,5-
dichlorophenyl)-3-oxobutanamide (123 mg, 0.50 mmol) according to
the general procedure THQ to give 138 mg (63%) of a white solid (tR =
10.51 min, purity 96.2% by HPLC) after purification by filtration
followed by washing with IPA: 1H NMR (500 MHz, DMSO-d6) δ 9.21
(s, 1H), 9.19 (s, 1H), 8.82 (s, 1H), 7.76 (d, J = 2.6 Hz, 1H), 7.57 (s,
1H), 7.50 (d, J = 8.6 Hz, 1H), 7.24 (dd, J = 8.6, 2.6 Hz, 1H), 5.30 (s,
1H), 2.49−2.46 (m, 2H), 2.30−2.24 (m, 2H), 2.23 (s, 3H), 1.96−1.74
(m, 2H); 13CNMR (101MHz, DMSO-d6) δ 194.0, 166.5, 152.9, 152.3,
144.7, 140.1, 139.4, 136.5, 131.4, 130.7, 125.6, 125.4, 125.0, 109.0,
106.8, 36.6, 30.0, 26.2, 20.8, 17.7; ESI-HRMS calcd for
C20H18Cl2N3O2S (M + H)
+ 434.0491; found, 434.0508.
N-(2,5-Dichlorophenyl)-2-methyl-5-oxo-4-(thiazol-4-yl)-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (49). Com-
pound 49 was prepared from thiazole-4-carbaldehyde (58 mg, 0.51
mmol), 3-aminocyclohex-2-en-1-one (56 mg, 0.50 mmol), andN-(2,5-
dichlorophenyl)-3-oxobutanamide (124 mg, 0.50 mmol) according to
the general procedure THQ to give 130 mg (60%) of a white solid (tR =
11.31 min, purity 98.3% by HPLC) after purification by filtration
followed by washing with IPA: 1HNMR (500MHz, DMSO-d6) δ 10.92
(s, 1H), 9.32 (s, 1H), 9.14 (d, J = 2.1 Hz, 1H), 8.16 (d, J = 2.5 Hz, 1H),
7.54 (d, J = 8.6 Hz, 1H), 7.19 (dd, J = 8.6, 2.4 Hz, 1H), 7.11 (d, J = 1.3
Hz, 1H), 5.04 (s, 1H), 2.65−2.53 (m, 2H), 2.37−2.25 (m, 2H), 2.10 (s,
3H), 2.07−1.95 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 194.3,
166.7, 159.6, 154.8, 153.5, 143.8, 137.4, 131.5, 130.7, 124.2, 123.0,
122.7, 114.1, 107.3, 106.0, 36.7, 32.3, 26.3, 20.8, 18.0; ESI-HRMS calcd
for C20H18Cl2N3O2S (M + H)
+ 434.0491; found, 434.0513.
N-(2,5-Dichlorophenyl)-2-methyl-4-(oxazol-4-yl)-5-oxo-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (50). Com-
pound 50 was prepared from oxazole-4-carbaldehyde (49 mg, 0.50
mmol), 3-aminocyclohex-2-en-1-one (56 mg, 0.50 mmol), and N-(2,5-
dichlorophenyl)-3-oxobutanamide (123 mg, 0.50 mmol) according to
the general procedure THQ to give 77 mg (37%) of a brown solid (tR =
10.77 min, purity 97.8% by HPLC) after purification by filtration
followed by washing with IPA: 1HNMR (500MHz, DMSO-d6) δ 10.11
(s, 1H), 9.24 (s, 1H), 8.34 (d, J = 1.0 Hz, 1H), 8.10 (d, J = 2.6 Hz, 1H),
7.69−7.62 (m, 1H), 7.53 (d, J = 8.6 Hz, 1H), 7.20 (dd, J = 8.6, 2.6 Hz,
1H), 4.83 (s, 1H), 2.58−2.44 (m, 2H), 2.33−2.20 (m, 2H), 2.12 (s,
3H), 2.04−1.88 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 194.1,
166.5, 153.4, 152.2, 143.1, 142.8, 137.1, 135.0, 131.5, 130.7, 124.6,
123.4, 123.3, 106.3, 105.3, 36.6, 28.4, 26.3, 20.7, 17.9; ESI-HRMS calcd
for C20H18Cl2N3O3 (M + H)
+ 418.0720; found, 418.0733.
N-(2,5-Dichlorophenyl)-2-methyl-4-(oxazol-2-yl)-5-oxo-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (51). Com-
pound 51 was prepared from oxazole-2-carbaldehyde (49 mg, 0.50
mmol), 3-aminocyclohex-2-en-1-one (56 mg, 0.50 mmol), and N-(2,5-
dichlorophenyl)-3-butanamide (123 mg, 0.50 mmol) according to the
general procedure THQ to give 12 mg (6%) of a pale yellow solid (tR =
10.43 min, purity 99.0% by HPLC) after purification by flash
chromatography (Reveleris X2, 12 g, EtOAc in petroleum ether, 0 to
100%): 1H NMR (400 MHz, CDCl3) δ 9.69 (s, 1H), 9.23 (s, 1H), 7.91
(d, J = 0.7 Hz, 1H), 7.88 (d, J = 2.5 Hz, 1H), 7.52 (d, J = 8.6 Hz, 1H),
7.24 (dd, J = 8.6, 2.6 Hz, 1H), 7.08 (d, J = 0.7 Hz, 1H), 5.19 (s, 1H),
2.58−2.47 (m, 2H), 2.34−2.24 (m, 2H), 2.15 (s, 3H), 2.03−1.81 (m,
2H); 13C NMR (101 MHz, CDCl3) δ 194.1, 166.4, 165.7, 153.3, 141.1,
139.0, 136.8, 131.4, 130.7, 126.7, 125.2, 124.6, 104.9, 103.9, 36.5, 31.8,
26.3, 20.9, 17.7; ESI-HRMS calcd for C20H17Cl2N3NaO3 (M + Na)
+
440.0539; found, 440.0539.
4-(Aminomethyl)-N-(2,5-dichlorophenyl)-2-methyl-5-oxo-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide Hydrochlor-
ide (52). Compound 52 was prepared from tert-butyl ((3-((2,5-
dichlorophenyl)carbamoyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroqui-
nolin-4-yl)methyl)carbamate (8 mg, 17 μmol) which was dissolved in 1
mL of 4 M HCl in 1,4-dioxane at 0 °C. The mixture was stirred
overnight at room temperature and concentrated to give 7 mg (quant.)
of a yellow solid (tR = 7.00 min, purity 96.4% byHPLC):
1HNMR (400
MHz, DMSO-d6) δ 9.75 (s, 1H), 9.15 (s, 1H), 7.86 (d, J = 2.5 Hz, 1H),
7.78 (s, 2H), 7.55 (d, J = 8.7 Hz, 1H), 7.30 (dd, J = 8.6, 2.6 Hz, 1H),
4.00 (t, J = 4.2 Hz, 1H), 2.80−2.69 (m, 1H), 2.64−2.54 (m, 1H), 2.46−
2.21 (m, 4H), 2.18 (s, 3H), 2.06−1.97 (m, 1H), 1.94−1.83 (m, 1H);
13C NMR (101 MHz, DMSO-d6) δ 195.1, 167.3, 155.2, 139.6, 136.3,
131.3, 130.7, 126.08, 126.07, 125.8, 104.3, 104.2, 42.9, 36.6, 30.9, 26.4,
20.4, 17.8; ESI-HRMS calcd for C18H20Cl2N3O2 (M + H)
+ 380.0927;
found, 380.0925.
N-(2,5-Dichlorophenyl)-2-methyl-5-oxo-4-(piperidin-4-yl-
methyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide Hy-
drochloride (53). Compound 53 was prepared from tert-butyl 4-
((3-((2,5-dichlorophenyl)carbamoyl)-2-methyl-5-oxo-1,4,5,6,7,8-hex-
ahydroquinolin-4-yl)methyl)piperidine-1-carboxylate (30 mg, 55
μmol) which was dissolved in 2 mL of 4 M HCl in 1,4-dioxane at 0
°C. The mixture was stirred overnight at room temperature and
concentrated to give 26 mg (quant.) of a yellow solid (tR = 7.27 min,
purity 95.1% by HPLC): 1H NMR (400 MHz, DMSO-d6) δ 9.23 (s,
1H), 9.01 (s, 1H), 8.82 (d, J = 9.6Hz, 1H), 8.62−8.48 (m, 1H), 7.80 (d,
J = 2.5 Hz, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.26 (dd, J = 8.6, 2.6 Hz, 1H),
3.85−3.77 (m, 2H), 3.24−3.10 (m, 2H), 2.75−2.59 (m, 2H), 2.53−
2.36 (m, 2H), 2.35−2.18 (m, 2H), 2.15 (s, 3H), 2.07−1.68 (m, 4H),
1.52−1.38 (m, 2H), 1.32−1.06 (m, 4H); 13CNMR (101MHz, DMSO-
d6) δ 194.6, 167.5, 152.9, 138.4, 136.7, 131.3, 130.7, 125.51, 125.50,
125.0, 109.3, 108.8, 43.6, 43.1, 43.0, 36.8, 29.2, 28.8, 28.4, 28.1, 26.4,
20.8, 17.5; ESI-HRMS calcd for C23H28Cl2N3O2 (M + Na)
+ 448.1553;
found, 448.1568.
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N-(2,5-Dichlorophenyl)-4-((2-(diethylamino)ethoxy)-
methyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-
carboxamide (54). 2-(Diethylamino)ethan-1-ol (500 mg, 4.27
mmol) was added dropwise to a suspension of NaH (266 mg, 50%)
in 5mL of dry THF. Themixture was heated at 50 °C for 10min, before
dropwise addition of 2-bromo-1,1-diethoxyethane (0.77 mL, 5.12
mmol). The mixture was afterward heated to 100 °C overnight. The
reaction mixture was cooled down, quenched with water, and extracted
with EtOAc (×3). The organic phases were combined, washed with
brine, dried over Na2SO4, and concentrated. The crude 2-(2,2-
diethoxyethoxy)-N,N-diethylethan-1-amine was used directly in the
next step.
N,N-Diethyl-2-(2-oxoethoxy)ethan-1-aminium 2,2,2-trifluoroace-
tate was prepared from 2-(2,2-diethoxyethoxy)-N,N-diethylethan-1-
amine (730 mg, 3.13 mmol) and TFA (5 mL), and the mixture was
stirred at rt overnight. Afterward, the reactionmixture was concentrated
and dried, and the crude was used in the next step without any further
purification: 1H NMR (400 MHz, CDCl3) δ 9.61 (s, 1H), 9.18 (s, 1H),
4.31 (s, 2H), 3.93−3.86 (m 2H), 3.45−3.25 (m, 6H), 1.37 (t, J = 7.3
Hz, 6H); ESI-HRMS calcd for C8H18NO2 (M + H)
+ 160.1332; found,
160.1325.
Compound 54 was prepared from N,N-diethyl-2-(2-oxoethoxy)-
ethan-1-aminium 2,2,2-trifluoroacetate (138 mg, 0.51 mmol), 3-
aminocyclohex-2-en-1-one (56 mg, 0.51 mmol), and N-(2,5-dichlor-
ophenyl)-3-butanamide (125 mg, 0.51 mmol) according to the general
procedure THQ to give 15 mg (6%) of a pale yellow solid (tR = 7.38
min, purity 99.4% byHPLC) after purification by flash chromatography
(SiO2, MeOH in EtOAc, 0% to 8%):
1H NMR (400 MHz, CDCl3) δ
9.21 (s, 1H), 8.34 (d, J = 2.5 Hz, 1H), 7.28 (d, J = 8.6Hz, 1H), 6.99 (dd,
J = 8.6, 2.5 Hz, 1H), 6.21 (s, 1H), 4.18−4.11 (m, 1H), 3.67−3.52 (m,
2H), 3.31−3.22 (m, 2H), 2.69−2.62 (m, 2H), 2.59−2.40 (m, 8H),
2.37−2.25 (m, 5H), 2.10−2.91 (m, 3H), 0.97 (t, J = 7.2 Hz, 6H); 13C
NMR (101 MHz, CDCl3) δ 196.6, 167.3, 160.5, 155.1, 143.1, 136.3,
133.6, 130.0, 124.4, 121.7, 121.3, 107.2, 106.4, 74.9, 65.6, 56.7, 56.3,
51.5, 48.6, 47.9, 47.8, 36.9, 32.6, 27.3, 21.3, 18.9, 8.9; ESI-HRMS calcd
for C24H32Cl2N3O2 (M + Na)
+ 480.1815; found, 480.1828.
tert-Butyl((3-((2,5-dichlorophenyl)carbamoyl)-2-methyl-5-
oxo-1,4,5,6,7,8-hexahydroquinolin-4-yl)methyl)carbamate
(55). Compound 55 was prepared from tert-butyl (2-oxoethyl)-
carbamate (80 mg, 0.50 mmol), 3-aminocyclohex-2-en-1-one (56 mg,
0.50 mmol), and N-(2,5-dichlorophenyl)-3-oxobutanamide (125 mg,
0.51 mmol) according to the general procedure THQ to give 41 mg
(17%) of a white solid (tR = 11.76 min, purity 97.2% by HPLC) after
purification by flash chromatography (SiO2, EtOAc):
1H NMR (400
MHz, CD3OD) δ 8.13 (d, J = 1.4 Hz, 1H), 7.45 (d, J = 8.6Hz, 1H), 7.19
(dd, J = 8.6, 2.4 Hz, 1H), 4.07−3.94 (m, 1H), 3.16−2.93 (m, 2H),
2.60−2.25 (m, 4H), 2.16 (s, 3H), 2.12−1.94 (m, 2H), 1.41 (s, 9H); 13C
NMR (101 MHz, CD3OD) δ 198.9, 170.5, 159.0, 157.4, 140.0, 137.4,
133.9, 131.5, 126.8, 125.9, 125.6, 108.9, 108.2, 79.9, 45.5, 37.8, 35.1,
28.8, 27.9, 22.2, 17.7; ESI-HRMS calcd for C23H28Cl2N3O4 (M + H)
+
480.1451; found, 480.1445.
tert-Butyl 4-((3-((2,5-dichlorophenyl)carbamoyl)-2-methyl-
5-oxo-1,4,5,6,7,8-hexahydroquinolin-4-yl)methyl)piperidine-
1-carboxylate (56).Compound 56was prepared from tert-butyl 4-(2-
oxoethyl)piperidine-1-carboxylate (115 mg, 0.50 mmol), 3-amino-
cyclohex-2-en-1-one (113 mg, 1.02 mmol), and N-(2,5-dichlorophen-
yl)-3-oxobutanamide (125 mg, 0.51 mmol) according to the general
procedure THQ to give 142 mg (52%) of a white solid (tR = 13.21 min,
purity 99.1% by HPLC) after purification by flash chromatography
(SiO2, EtOAc):
1H NMR (400 MHz, acetone-d6) δ 8.50 (d, J = 2.5 Hz,
0.3H), 8.49 (d, J = 2.5 Hz, 0.7H), 8.39 (br s, 1H), 8.15 (br s, 1H), 7.49
(d, J = 8.6 Hz, 1H), 7.15 (dd, J = 8.6, 2.6 Hz, 1H), 4.05−3.88 (m, 3H),
2.65−2.43 (m, 4H), 2.30 (s, 3H), 2.41−2.18 (m, 2H), 2.03−1.87 (m,
3H), 1.60 (d, J = 13.0 Hz, 1H), 1.40 (s, 9H), 1.46−1.17 (m, 3H), 1.06−
0.90 (m, 2H); 13C NMR (101 MHz, acetone-d6) δ 195.4, 167.7, 155.1,
152.8, 152.7, 142.4, 137.7, 133.5, 131.1, 124.9, 124.8, 122.7, 122.6,
111.7, 109.2, 109.1, 79.0, 45.1, 44.7 (br s), 37.8, 33.8, 33.3, 32.8, 28.6,
27.64, 27.56, 22.0, 18.5, 18.4 (contains rotamers); ESI-HRMS calcd for
C28H35Cl2N3NaO4 (M + Na)
+ 570.1897; found, 570.1880.
N - (2,5-Dichlorophenyl)-2-methyl-5-oxo-4-propyl-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (57). Com-
pound 57 was prepared from butyraldehyde (65 μL, 0.72 mmol), 3-
aminocyclohex-2-en-1-one (70 mg, 0.63 mmol), and N-(2,5-dichlor-
ophenyl)-3-oxobutanamide (155 mg, 0.63 mmol) according to the
general procedure THQ to give 85mg (34%) of a pale yellow solid (tR =
12.34 min, purity 96.1% by HPLC) after purification by flash
chromatography (SiO2, EtOAc/petroleum ether, 1:1):
1H NMR (500
MHz, DMSO-d6) δ 9.14 (s, 1H), 8.72 (s, 1H), 7.80 (d, J = 2.5 Hz, 1H),
7.53 (d, J = 8.6 Hz, 1H), 7.25 (dd, J = 8.6, 2.5 Hz, 1H), 3.85 (t, J = 4.7
Hz, 1H), 2.44−2.33 (m, 2H), 2.30−2.15 (m, 2H), 2.12 (s, 3H), 1.94−
1.77 (m, 2H), 1.39−1.12 (m, 4H), 0.79 (t, J = 7.1 Hz, 3H); 13C NMR
(101MHz, DMSO-d6) δ 194.5, 167.5, 152.8, 138.8, 136.7, 131.4, 130.6,
125.51, 125.46, 125.1, 108.9, 108.1, 38.6, 36.9, 31.1, 26.3, 21.0, 17.6,
17.5, 14.3; ESI-HRMS calcd for C20H23Cl2N2O2 (M + H)
+ 393.1131;
found, 393.1112.
N-(2-Chlorophenyl)-2-methyl-5-oxo-4-propyl-1,4,5,6,7,8-
hexahydroquinoline-3-carboxamide (58). Compound 58 was
prepared from butyraldehyde (36 mg, 0.50 mmol), 3-aminocyclohex-2-
en-1-one (55 mg, 0.50 mmol), and N-(2-chlorophenyl)-3-oxobutana-
mide (105mg, 0.50 mmol) according to the general procedure THQ to
give 38mg (21%) of a pale yellow solid (tR = 11.07min, purity 97.3% by
HPLC) after purification by flash chromatography (Reveleris X2, 24 g,
EtOAc/petroleum ether, 3:2): 1H NMR (400 MHz, CDCl3) δ 8.34
(dd, J = 1.5, 8.3 Hz, 1H), 8.03 (s, 1H), 7.37 (dd, J = 1.5, 8.0 Hz, 1H),
7.29−7.23 (m, 1H), 7.05−6.99 (m, 1H), 6.42 (s, 1H), 3.96 (t, J = 5.5
Hz, 1H), 2.53−2.40 (m, 3H), 2.37−2.27 (m, 4H), 2.08−1.93 (m, 2H),
1.64−1.20 (m, 4H), 0.86 (t, J = 7.2 Hz, 3H); 13C NMR (101 MHz,
CDCl3) δ 195.9, 166.7, 151.7, 140.9, 135.1, 129.1, 127.5, 124.3, 123.4,
122.0, 111.2, 108.6, 39.0, 37.1, 31.5, 27.5, 21.2, 18.9, 18.3, 14.3; ESI-
HRMS calcd for C20H24ClN2O2 (M+Na)
+ 359.1521; found, 359.1537.
N-(3-Chlorophenyl)-2-methyl-5-oxo-4-propyl-1,4,5,6,7,8-
hexahydroquinoline-3-carboxamide (59). N-(3-Chlorophenyl)-
3-oxobutanamide was prepared from 2-chloroaniline (1.10 g, 8.61
mmol) and 2mL of methyl acetoacetate. The mixture was stirred at 110
°C overnight, cooled down, and dry loaded on silica. Purification by
flash chromatography (Reveleris X2, 12 g, EtOAc in petroleum ether, 0
to 100%) gave 536 mg (29%) of an off-white solid: 1H NMR (400
MHz, CDCl3) δ 9.28 (s, 1H), 7.68 (t, J = 2.0 Hz, 1H), 7.40−7.34 (m,
1H), 7.28−7.20 (m, 1H), 7.12−7.06 (m, 1H), 3.59 (s, 2H), 2.32 (s,
3H); 13C NMR (101 MHz, CDCl3) δ 205.3, 163.5, 138.6, 134.7, 130.0,
124.6, 120.3, 118.1, 49.4, 31.3; ESI-HRMS calcd for C10H10ClNNaO2
(M + Na)+ 234.0292; found, 234.0302.
Compound 59 was prepared from butyraldehyde (36 mg, 0.50
mmol), 3-aminocyclohex-2-en-1-one (55 mg, 0.50 mmol), and N-(3-
chlorophenyl)-3-oxobutanamide (105 mg, 0.50 mmol) according to
the general procedure THQ to give 25 mg (14%) of a pale yellow solid
(tR = 11.27 min, purity 97.5% by HPLC) after purification by flash
chromatography (Reveleris X2, 24 g, MeOH in DCM, 0 to 10%): 1H
NMR (400 MHz, CDCl3) δ 7.88 (s, 1H), 7.74 (t, J = 2 Hz, 1H), 7.35−
7.30 (m, 1H), 7.22 (t, J = 7.1Hz, 1H), 7.08−7.03 (m, 1H), 6.18 (s, 1H),
3.88 (t, J = 5.9 Hz, 1H), 2.52−2.39 (m, 3H), 2.35−2.26 (m, 1H), 2.25
(s, 3H), 2.07−1.94 (m, 2H), 1.49−1.19 (m, 4H), 0.83 (t, J = 7.1 Hz,
3H); 13C NMR (101 MHz, CDCl3) δ 196.2, 167.3, 151.9, 140.0, 139.5,
134.6, 129.8, 124.0, 120.4, 118.2, 111.0, 108.9, 39.1, 37.1, 31.7, 27.6,
21.2, 18.6, 18.2, 14.3; ESI-HRMS calcd for C20H23ClN2NaO2 (M +
Na)+ 381.1340; found, 381.1343.
N-(2-Chloro-5-methylphenyl)-2-methyl-5-oxo-4-propyl-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (60). N-(2-
Chloro-5-methylphenyl)-3-oxobutanamide was prepared from 2-
chloro-5-methylaniline (1.0 g, 7.06 mmol), 2 mL of methyl
acetoacetate, and a catalytic amount of potassium t-butoxide. The
mixture was heated in aMW reactor at 120 °C for 2 h. After completion,
the reaction mixture was cooled to rt, dry loaded on silica, and purified
by flash chromatography (SiO2, EtOAc/petroleum ether, 1:4) to yield
640 mg (40%) of a yellow solid: 1HNMR (400MHz, CDCl3) δ 9.49 (s,
1H), 8.15 (d, J = 1.4 Hz, 1H), 7.24 (d, J = 8.2 Hz, 1H), 6.88−6.84 (m,
1H), 3.63 (s, 2H), 2.34 (s, 3H), 2.32 (s, 3H); 13C NMR (101 MHz,
CDCl3) δ 204.6, 163.6, 137.7, 134.1, 128.7, 125.8, 122.6, 120.5, 49.9,
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31.2, 21.3; ESI-HRMS calcd for C11H12ClNNaO2 (M+Na)
+ 248.0449;
found, 248.0457.
Compound 60 was prepared from butyraldehyde (34 mg, 0.47
mmol), 3-aminocyclohex-2-en-1-one (52 mg, 0.47 mmol), and N-(2-
chloro-5-methylphenyl)-3-oxobutanamide (105 mg, 0.47 mmol)
according to the general procedure THQ to give 39 mg (22%) of a
pale yellow solid (tR = 11.63 min, purity 98.7% by HPLC) after
purification by flash chromatography (SiO2, EtOAc in petroleum ether,
50% to 70%): 1H NMR (400 MHz, CDCl3) δ 8.18 (d, J = 1.6 Hz, 1H),
7.99 (s, 1H), 7.23 (d, J = 8.2 Hz, 1H), 6.86−6.80 (m, 1H), 6.56 (s, 1H),
3.96 (t, J = 5.5 Hz, 1H), 2.54−2.39 (m, 3H), 2.37−2.26 (m, 7H), 2.07−
1.93 (m, 2H), 1.55−1.34 (m, 2H), 1.33−1.21 (m, 2H), 0.91−0.81 (m,
3H); 13C NMR (101MHz, CDCl3) δ 196.0, 166.8, 151.8, 140.8, 137.7,
134.6, 128.6, 125.2, 122.5, 120.4, 111.1, 108.7, 39.0, 37.1, 31.5, 27.5,
21.3, 21.2, 18.9, 18.3, 14.3; ESI-HRMS calcd for C21H25ClN2NaO2 (M
+ Na)+ 395.1497; found, 395.1513.
N-(2-Chloro-5-methoxyphenyl)-2-methyl-5-oxo-4-propyl-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (61). N-(2-
Chloro-5-methoxyphenyl)-3-oxobutanamide was prepared from 2-
chloro-5-methoxylaniline (1.0 g, 7.06 mmol), 2 mL of methyl
acetoacetate, and a catalytic amount of potassium t-butoxide. The
mixture was heated in aMW reactor at 120 °C for 2 h. After completion,
the reaction mixture was cooled to rt, dry loaded on silica, and purified
by flash chromatography (SiO2, EtOAc/petroleum ether, 1:4) to yield
617mg (30%) of a yellow solid: 1HNMR (400MHz, CDCl3) δ 9.59 (s,
1H), 8.04 (d, J = 3.0 Hz, 1H), 7.25 (d, J = 8.9 Hz, 1H), 6.61 (dd, J = 8.9,
3.0 Hz, 1H), 3.79 (s, 3H), 3.64 (s, 2H), 2.34 (s, 3H); 13C NMR (101
MHz, CDCl3) δ 204.6, 163.6, 158.8, 135.2, 129.3, 114.6, 111.2, 107.1,
55.6, 49.8, 31.2; ESI-HRMS calcd for C11H12ClNNaO3 (M + Na)
+
264.0398; found, 264.0389.
Compound 61 was prepared from butyraldehyde (36 mg, 0.50
mmol), 3-aminocyclohex-2-en-1-one (55 mg, 0.50 mmol), and N-(2-
chloro-5-methoxyphenyl)-3-oxobutanamide (120 mg, 0.50 mmol)
according to the general procedure THQ to give 48 mg (25%) of a
pale yellow solid (tR = 11.42 min, purity 97.6% by HPLC) after
purification by flash chromatography (SiO2, EtOAc in petroleum ether,
50% to 70%): 1H NMR (400 MHz, CDCl3) δ 8.07 (d, J = 3.0 Hz, 1H),
8.03 (s, 1H), 7.24 (d, J = 8.9 Hz, 1H), 6.66 (s, 1H), 6.58 (dd, J = 8.9, 3.0
Hz, 1H), 3.96 (t, J = 5.5 Hz, 1H), 3.81 (s, 3H), 2.53−2.40 (m, 3H),
2.37−2.26 (m, 4H), 2.07−1.89 (m, 2H), 1.55−1.45 (m, 1H), 1.44−
1.34 (m, 1H), 1.33−1.20 (m, 2H), 0.85 (t, J = 7.2 Hz, 3H); 13C NMR
(101 MHz, CDCl3) δ 196.0, 166.8, 158.9, 151.9, 140.9, 135.7, 129.2,
114.5, 111.1, 110.7, 108.8, 106.9, 55.7, 39.0, 37.1, 31.5, 27.5, 21.2, 18.8,
18.3, 14.3; ESI-HRMS calcd for C21H25ClN2NaO3 (M + Na)
+
411.1446; found, 411.1467.
4-Cyclopropyl-N-(2,5-dichlorophenyl)-2-methyl-5-oxo-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (62). Com-
pound 62 was prepared from cyclopropanecarbaldehyde (36 mg,
0.51 mmol), 3-aminocyclohex-2-en-1-one (56 mg, 0.51 mmol), and N-
(2,5-dichlorophenyl)-3-oxobutanamide (125 mg, 0.51 mmol) accord-
ing to the general procedure THQ to give 125 mg (63%) of a pale
yellow solid (tR = 11.85 min, purity 99.4% by HPLC) after purification
by flash chromatography (Reveleris X2, 24 g, EtOAc in petroleum
ether, 0 to 100%): 1H NMR (400 MHz, CDCl3) δ 8.46 (d, J = 2.5 Hz,
1H), 8.15 (s, 1H), 7.29 (d, J = 8.6 Hz, 1H), 7.00 (dd, J = 8.6, 2.5 Hz,
1H), 5.93 (s, 1H), 3.82 (d, J = 6.7 Hz, 1H), 2.57−2.42 (m, 3H), 2.39−
2.29 (m, 4H), 2.11−2.01 (m, 2H), 1.10−1.00 (m, 1H), 0.41−0.35 (m,
3H), 0.28−0.18 (m, 1H); 13CNMR (101MHz, CDCl3) δ 196.0, 166.8,
150.4, 142.2, 136.1, 133.4, 129.7, 124.1, 121.7, 121.2, 111.7, 106.3, 37.1,
32.3, 27.6, 21.2, 19.2, 18.0, 2.8, 2.7; ESI-HRMS calcd for
C20H20Cl2N2NaO2 (M + Na)
+ 413.0794; found, 413.0793.
4-Cyclopentyl-N-(2,5-dichlorophenyl)-2-methyl-5-oxo-
1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (63). Com-
pound 63 was prepared from cyclopentanecarbaldehyde (50 mg, 0.51
mmol), 3-aminocyclohex-2-en-1-one (56 mg, 0.51 mmol), andN-(2,5-
dichlorophenyl)-3-oxobutanamide (125 mg, 0.51 mmol) according to
the general procedure THQ to give 10 mg (5%) of a pale yellow solid
(tR = 12.83 min, purity 95.6% by HPLC) after purification by flash
chromatography (Reveleris X2, 24 g, EtOAc in petroleum ether, 0 to
100%): 1H NMR (400 MHz, DMSO-d6) δ 9.07 (s, 1H), 8.81 (s, 1H),
7.84 (d, J = 2.6 Hz, 1H), 7.53 (d, J = 8.6 Hz, 1H), 7.24 (dd, J = 8.6, 2.6
Hz, 1H), 3.90 (d, J = 6.1 Hz, 1H), 2.47−2.35 (m, 2H), 2.34−2.12 (m,
5H), 1.97−1.87 (m, 1H), 1.86−1.71 (m, 2H), 1.55−1.08 (m, 8H); 13C
NMR (101MHz, DMSO-d6) δ 194.7, 168.1, 152.8, 139.0, 136.7, 131.4,
130.6, 125.2, 124.9, 124.5, 108.6, 107.6, 48.0, 37.0, 33.7, 27.9, 27.8,
26.5, 24.1, 24.0, 20.8; ESI-HRMS calcd for C22H24Cl2N2NaO2 (M +
Na)+ 441.1107; found, 441.1090.
Inhibition of cAMP Assay. HEK293 Flp-In T-Rex cells stably
transfected with FFA3-eYFP receptors were incubated overnight with
doxycycline to induce expression, then harvested, and cryopreserved.
On the day of each experiment, cells were thawed and resuspended in
stimulation buffer. Assays were carried out using a 384-well plate format
with 3000 cells/well using the CisBio cAMP GS dynamic kit as per
manufacturer’s protocol. Compounds were tested for the ability to
inhibit 0.3 μM forskolin-induced cAMP production after co-incubation
for 1 h. Reactions were measured using a PHERAstar FS plate reader
(BMGLabtech, Aylesbury, UK).
Membrane Preparation.Membranes were isolated from Flp-In T-
REx HEK293 cells treated with 100 ng/mL doxycycline to induce
receptor expression. Cells were washed with ice-cold phosphate-
buffered saline and removed from dishes by scraping before being
centrifuged for 5min at 4 °C, 3000 rpm. Pellets were resuspended in TE
buffer (75 mMTris−HCl, 5 mM EDTA; pH 7.5) with the addition of a
protease inhibitor mixture (Roche Applied Science, West Sussex, UK).
This was then homogenized with a 5 mL hand-held homogenizer and
subsequently centrifuged at 1500 rpm for 5 min at 4 °C, from which the
supernatant was collected and further centrifuged at 50 000 rpm for 30
min at 4 °C. The resulting pellet was resuspended in TE buffer, and the
protein content was measured using a BCA protein assay kit (Pierce,
Fisher Scientific, Loughborough, UK).
[35S]GTPγS Incorporation Assay. [35S]GTPγS binding assays
were performed in reactions with 5 μg of cell membrane protein
preincubated for 15min at 25 °C in assay buffer (50mMTris−HCl, pH
7.4, 10 mMMgCl2, 100 mMNaCl, 1 mMEDTA, 1 μMGDP, and 0.1%
fatty acid-free bovine serum albumin) containing the indicated
concentrations of ligands. Reactions were initiated with the addition
of [35S]GTPγS at 50 nCi per tube; reactions were terminated after 1 h of
incubation at 25 °Cby rapid filtration throughGF/C glass filters using a
24-well Brandel cell harvester (Alpha Biotech, Glasgow, UK). Unbound
radioligand was removed from filters by washing three times with ice-
cold wash buffer (50 mM Tris−HCl, pH 7.4, and 10 mMMgCl2), and
[35S]GTPγS binding was determined by liquid scintillation spectrom-
etry.
Physicochemical Properties. Solubility and log D7.4 measure-
ments were performed in accordance to the previously published
procedures.35
Microsomal Stability. The study was performed by Bienta (www.
bienta.net). Mouse hepatic microsomes were isolated from pooled and
perfused livers of male BALB/c mice (n = 50). Isolation was performed
according to the standard protocol.36 The batches of microsomes were
tested for quality control using Imipramine and Propranolol as
reference compounds.
Microsomal incubations were carried out in 96-well plates in 5
aliquots of 40 μL each (one for each time point). Liver microsomal
incubation medium comprised PBS (100 mM, pH 7.4), MgCl2 (3.3
mM), NADPH (3 mM), glucose-6-phosphate (5.3 mM), and glucose-
6-phosphate dehydrogenase (0.67 units/mL) with 0.42 mg of liver
microsomal protein per ml. In the control reactions, the NADPH-
cofactor systemwas substituted with PBS. Test compounds (2 μM, final
solvent concentration 1.6%) were incubated with microsomes at 37 °C,
shaking at 100 rpm. Each reaction was performed in duplicates. Five
time points over 40 min were analyzed. The reactions were stopped by
adding 12 volumes of 90% acetonitrile−water to incubation aliquots,
followed by protein sedimentation by centrifuging at 5500 rpm for 3
min. Each reaction was performed in duplicates. Supernatants were
analyzed using HPLC-MS/MS on an API 3000 PE instrument.
In Vivo Pharmacokinetics. The study was performed by Bienta
(www.bienta.net). Study design, animal selection, handling, and
treatment were all in accordance with the Enamine PK study protocols
and Institutional Animal Care and Use Guidelines. Animal treatment
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and plasma samples preparation were conducted by the Animal
Laboratory personnel at Enamine/Bienta. Male BALB/c mice (8−10
weeks old, body weight: 1 17.2 g to 29.5 g and average body weight
across all groups 22.4 ± 2.95 g; 16 18.0 g to 28.6 g and average body
weight across all groups 22.8 ± 2.34 g; 57 20.0 g to 37.4 g and average
body weight across all groups 27.0 ± 4.71 g; 63 17.6 g to 28.1 g and
average body weight across all groups 22.0 ± 2.61 g) were used in this
study. The animals were randomly assigned to the treatment groups
before the pharmacokinetic study; all animals were fasted for 4 h before
dosing. Nine time points (5, 15, 30, 60, 120, 240, 360, 480, and 1440
min) were set for this pharmacokinetic study. Each of the time point
treatment group included four animals. There was also a control group
of two animals. Compound 1, 16, 57, and 63 in a vehicle (DMSO−
Cremophor EL−water w/5% mannitol, 1:1:8) was dosed at 10 mg/kg
po or 5 mg/kg iv. Dosing volumes of compounds or vehicle was 5 mL/
kg. Mice were injected iv with 2,2,2-tribromoethanol at the dose of 150
mg/kg prior to drawing the blood. Blood collection was performed
from the orbital sinus in microtainers containing K2EDTA. Animals
were sacrificed by cervical dislocation after the blood sample collection.
All samples were immediately processed, flash-frozen, and stored at
−70 °C until subsequent analysis. Before analysis, plasma samples (50
μL) were added acetonitrile-methanol (1:1, v/v, 200 μL) containing an
internal standard (IS-10784, C20H26N8, Mw 378.47) 200 ng/mL for 1,
63 400 ng/mL for 16, or 16 200 ng/mL for 57 and 63, respectively).
After mixing by pipetting and centrifuging for 4 min at 6000 rpm, 0.5−1
μL of each supernatant was analyzed byHPLC-MS/MS on an API 3000
PE instrument.
Dorsal Root Ganglion Assay. Colonic innervating DRGs were
isolated from the T9-L2 region of the spinal cord of C57/BL6mice and
from FFA3 knock-out animals and immediately placed in cold Hanks’
balanced salt solution (HBSS; Sigma-Aldrich). Isolated DRGs were
initially digested with HBSS containing L-cysteine (0.3 mg/mL) and
papain (2.0 mg/mL) for 20 min at 37 °C. The solution was removed
and replaced with HBSS contain collagenase (4.0 mg/mL) and dispase
(4.0 mg/mL) (20 min at 37 °C) for further digestion. The collagenase
solution was then replaced withDMEM to stop the reaction. TheDRGs
were finally dissociated by mechanical trituration using a pipette.
Dissociated cells were plated on matrigel-coated coverslips and placed
in an incubator (37 °C and 5% CO2). Following a 2 h incubation, cells
were flooded with 90% DMEM (Sigma) supplemented with 10% fetal
calf serum and 1% PenStrep and further incubated overnight at 37 °C
and 5% CO2.
To measure intracellular calcium and its potential regulation,
dissociated cells on the coverslips were loaded with Fura 8-AM (3
μM) (Stratech Scientific Limited) for 20 min at 37 °C in the dark.
Coverslips were then placed in a recording chamber and mounted onto
an inverted fluorescent microscope (Nikon TE2000-E; Nikon Instru-
ments, Melville, NY) equipped with a (NA = 1.3) oil-immersion Super
Fluor objective lens (×40), an Optoscan monochromator (Cairn
Research, Faversham, Kent, UK), and a digital Cool Snap-HQ CCD
camera (Roper Scientific/Photometrics, Tucson, AZ). Illumination of
the preparation was achieved by a Meta Fluor imaging software
(Molecular Devices, San Jose CA, version 7.8.8).
Cluster of cells were randomly selected for real time imaging and
continuously perfused with HEPES buffer (composition: HEPES 10
mM, NaCl 135 mM, glucose 10 mM, KCl 5 mM, CaCl2 2 mM and
MgCl2 1 mM, pH 7.4) for 20 min at room temperature. All test ligands
were diluted in HEPES buffer and perfused through the chamber for 3
min, followed by a final application of the Ca2+ ionophore ionomycin (5
μM), as a positive control.
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